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  ABSTRACT 
Overdose of acetaminophen (APAP) is the major cause of acute liver failure (ALF) in 
the western world with very limited treatment options. Recent studies suggest that liver 
regeneration is a critical determinant of final recovery and overall survival following 
APAP overdose. Stimulating liver regeneration in patients of APAP-induced ALF holds a 
great therapeutic potential. However, development of novel regenerative therapies for 
ALF is hampered because the mechanisms of liver regeneration after APAP-induced 
ALF are not completely known. The focus of this research was to investigate the 
mechanisms of liver regeneration after APAP-induced hepatotoxicity in mice.  
Firstly, we identified potential regulators of liver regeneration following APAP-induced 
hepatotoxicity using a novel incremental dose model. Liver injury and regeneration were 
studied in C57BL/6 mice treated with either 300 mg/kg (APAP300) or 600 mg/kg 
(APAP600) APAP. Mice treated with APAP300 developed extensive liver injury initially, 
followed by robust liver regeneration, resulting in resolution of the injury. In contrast, 
mice treated with APAP600 exhibited significant liver injury, but substantially delayed 
and attenuated liver regeneration resulting in sustained injury and decreased survival. 
The inhibition of liver regeneration in APAP600 group was associated with cell cycle 
arrest and decreased Cyclin D1 expression. Further analysis revealed that several 
known regenerative pathways including IL-6/STAT-3, growth factor signaling via 
EGFR/c-Met/MAPK pathways were activated even in APAP600 group where 
regeneration was inhibited. However, canonical Wnt/β-catenin and NF-κB pathways 
were activated only in APAP300 treated mice, where liver regeneration was stimulated.  
 
   
  
iv
Next, we investigated role of Wnt/β-catenin in further detail. ChIP analysis revealed 
decreased binding of β-catenin to Cyclin D1 promoter in APAP600 group correlating 
with decreased cyclin D1 induction and impaired liver regeneration. Overexpression of a 
stable form of β-catenin (S45D) in mice resulted in improved liver regeneration following 
APAP overdose. Inactivation of GSK3, an upstream negative regulator β-catenin, was 
found to be positively associated with β-catenin activation and liver regeneration. GSK3 
inactivation was remarkably reduced in APAP600 group, where liver regeneration was 
attenuated and delayed. Treatment with a selective GSK3 inhibitor (L803-mts), as late 
as 4 hr after APAP600, resulted in early initiation of liver regeneration and improved 
survival in mice. Early hepatocyte proliferation after GSK3 inhibition was due to rapid 
induction of cyclin D1 secondary to increased activation of β-catenin signaling.  
Finally, we investigated the role of EGFR signaling in liver regeneration, which was 
dose-dependently activated after APAP overdose. Surprisingly, early EGFR inhibition (1 
hr post-APAP) by treatment with an irreversible EGFR inhibitor, canertinib, strikingly 
attenuated APAP hepatotoxicity suggesting role of EGFR in development of APAP 
hepatotoxicity. Delayed EGFR inhibition, 12 hr post-APAP, did not alter initial injury but 
caused cell cycle arrest, remarkable impairment of liver regeneration and decreased 
survival after APAP overdose (APAP300) in mice.  
Overall, these studies comprehensively investigated the mechanisms of liver 
regeneration after APAP-induced ALF and will pave the road for future therapeutic and 
mechanistic research on liver regeneration after APAP-induced ALF. 
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1.1 ACETAMINOPHEN (APAP) AND ITS HEPATOTOXICITY 
Acetaminophen (APAP) is the most commonly used over-the-counter (OTC) analgesic 
and anti-pyretic drug across the world. APAP is present in numerous formulations either 
alone or in combination with other active ingredients. Although, APAP is considered 
very safe at therapeutic doses, overdose of APAP can cause severe liver damage and 
acute liver failure (ALF). In fact, APAP overdose is the foremost cause of ALF in the US 
accounting for approximately 50% of all the ALF cases (Lee 2012, Bernal, Lee et al. 
2015). APAP overdose is associated with more than 78,000 emergency room visits, 
33,000 hospitalizations and around 500 deaths every year in the US (Budnitz, 
Lovegrove et al. 2011, Manthripragada, Zhou et al. 2011). While majority of APAP 
overdose cases are intentional (around 70%), cases of therapeutic misadventures are 
also frequent (Budnitz, Lovegrove et al. 2011). Extensive research has been done to 
study the mechanism of APAP toxicity, but the current treatment options are very 
limited. N-acetylcysteine (NAC) is the current standard of care for APAP overdose 
patients, which is effective only at an early stage (Yang, Miki et al. 2009, Bernal, Lee et 
al. 2015). Ultimate option is liver transplantation, which is complicated by issues such as 
donor availability, graft rejections, long-term immunosuppression and exorbitant costs 
(Keeffe 2001). 
At therapeutic doses, majority of the APAP (>85%) undergoes conjugation reaction with 
glucuronide or sulfate followed by excretion. Remaining APAP (5-15%) is metabolized 
to a reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) by CYP450 enzymes 
(mainly CYP2E1 and CYP1A2) (Nelson 1990, Zaher, Buters et al. 1998). This 
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metabolite is toxic, but gets rapidly conjugated to glutathione and converted into non-
toxic metabolite. In case of APAP overdose, there is excess production of NAPQI, which 
depletes cellular glutathione and form adducts with cellular proteins by reacting with 
sulfhydryl groups of cysteine residues. Mitochondria are the critical target of APAP 
toxicity and APAP adduct formation with mitochondrial proteins is considered important 
for toxicity initiation (Meyers, Beierschmitt et al. 1988, Tirmenstein and Nelson 1989, 
Jaeschke, McGill et al. 2012). This leads to mitochondrial dysfunction and generation of 
reactive oxygen species (ROS) in mitochondria. Additionally, superoxide radicals react 
with nitric oxide to form the highly potent oxidant, peroxynitrite, in mitochondria. Initial 
mitochondrial stress is considered not sufficient to cause hepatocyte necrosis and is 
exacerbated by a plethora of intracellular signaling events, which are not completely 
understood. c-Jun N-terminal kinase (JNK) activation, its mitochondrial translocation 
and interaction with the mitochondrial outer membrane protein Sab (SH3BP5) is 
considered one of such important signaling events (Hanawa, Shinohara et al. 2008, 
Win, Than et al. 2011, Jaeschke, Xie et al. 2014). Mitochondrial dysfunction and 
oxidative damage eventually lead to opening of the mitochondrial permeability transition 
(MPT) pore. This results in release of endonucleases such as apoptosis-inducing factor 
(AIF) and endonuclease G from the mitochondrial intermembrane space into the cytosol 
that cause DNA damage. The ultimate consequence is hepatocellular necrosis 
specifically in the centrilobular region of the liver (Jaeschke, McGill et al. 2011, 
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1.2 LIVER REGENERATION 
Liver has an extraordinary capacity to regenerate upon loss of liver tissue. Liver 
regeneration can occur as a compensatory response to toxin-induced liver injury, 
surgical resection, infection or trauma. Liver regeneration is seen in all vertebrates even 
after losing considerable amount of liver mass. Regenerative capacity of liver is long 
known and described even in ancient Greek mythology. Liver regeneration was first 
experimentally described by Higgins and Anderson in 1931, using rodent model of two-
third partial hepatectomy (PH). PH is still the most widely studied model of liver 
regeneration in which two-third of the liver is surgically removed and liver re-grows 
precisely to its original size within few days (5-7 days in rats and mice).  After PH, 
virtually all the remaining cells undergo 2-3 round of replication to restore original liver 
mass by compensatory hyperplasia (Michalopoulos 2007, Michalopoulos 2013, 
Michalopoulos 2014).  
The mechanisms of liver regeneration after PH have been extensively studied for 
decades. The process of liver regeneration is highly orchestrated and involves complex 
network of, often redundant, signaling pathways involving cytokines (such as tumor 
necrosis factor-α: TNFα and interleukin 6: IL6) and growth factors (such as hepatocyte 
growth factor: HGF, epidermal growth factor: EGF and transforming growth factor-α: 
TGFα). In brief, there are two different schools of thoughts regarding the mechanism of 
liver regeneration after PH. According to paradigm put forth by Nelson Fausto, cytokines 
initiate the process by priming the hepatocytes so that they are readily responsive to 
proliferative stimuli. This is followed by growth factors mediated entry into cell cycle and 
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progression through cell cycle leading to proliferation (Fausto 2000, Fausto, Campbell 
et al. 2006). In comparison, according to the theory put forth by George Michalopoulos, 
there is no demarcation in the time frame of action of growth factors and cytokines. 
Rather, there are some primary mitogens (such as HGF and ligands of EGF receptor), 
which can directly stimulate hepatocytes proliferation even in serum free media stand-
alone. Others are secondary mitogens such as IL6 and TNFα, which assist hepatocytes 
proliferation leading to orchestrated liver regeneration events. It is interesting to note 
that abolition of any of these signaling pathways alone does not inhibit liver regeneration 
permanently (except HGF/met) but only delays it, highlighting the redundancy of the 
pathways involved in liver regeneration (Michalopoulos and DeFrances 1997, 
Michalopoulos 2007). Apart, from classic regenerative response to loss of liver tissue, 
liver growth also occurs in adaptive physiological events such as during pregnancy. 
Further, many xenobiotics (such as phenobarbital and fibrate drugs) can stimulate 
hepatocyte proliferation and cause liver enlargement in absence of liver injury via 
activation of nuclear receptors (such as constitutive androstane receptor: CAR and 
peroxisome proliferator-activated receptor-α: PPAR-α). Despite decades of extensive 
research to understand the phenomenon of liver regeneration, the exact mechanism are 
still not completely understood; especially the events that terminates liver regeneration 
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1.3 LIVER REGENERATION: CRITICAL DETERMINANT OF FINAL OUTCOME 
AFTER CHEMICAL-INDUCED LIVER TOXICITY 
Liver regeneration is also observed as a compensatory response to liver injury mediated 
by toxicants such as thioacetamide (Mangipudy, Chanda et al. 1995), carbon 
tertrachloride (Rao, Mangipudy et al. 1997), chloroform  (Anand, Soni et al. 2003) and 
acetaminophen (Bajt, Knight et al. 2003, Apte, Singh et al. 2009). Data on 
hepatotoxicants, in general, suggest that liver regeneration follows the principles of 
dose-response (Mehendale 2005). Studies indicate that liver regeneration following 
toxicant-induced liver injury increases proportionately to the extent of liver injury, but 
only up-to a threshold dose. Doses higher than the threshold dose actually inhibit liver 
regeneration (Mangipudy, Chanda et al. 1995, Anand, Murthy et al. 2003, Mehendale 
2005). In fact, liver regeneration plays a critical role in determination of final outcome of 
injury such that timely stimulation of regeneration leads to regression of injury but 
delayed or inhibited regeneration culminates in progression of injury and death 
(Mehendale 2005). Importance of liver regeneration in toxic injury is especially 
highlighted by experiments in which liver regeneration was manipulated. For example, 
inhibition of liver regeneration, with anti-mitotic agents such as colchicine, following liver 
injury induced by several toxicants resulted in exacerbation of injury. Similarly, 
stimulation of liver regeneration in these cases inhibited progression of injury resulting in 
better survival (Mehendale 2005).  
Similar to other hepatotoxicants, APAP-induced liver injury is followed by compensatory 
liver regeneration, where in, the hepatocytes in closest proximity to the necrotic zones 
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divide and replace dead cells leading to recovery. Several lines of evidence indicate the 
important of role of liver regeneration in determining outcome after APAP-induced liver 
injury. For instance, treatment with IL6 (James, Lamps et al. 2003), stem cell factor (Hu 
and Colletti 2008), VEGF (Donahower, McCullough et al. 2010) and glutathione (Bajt, 
Knight et al. 2003) enhanced liver regeneration resulting in regression of injury or 
enhanced survival after APAP-induced toxicity in mice. Further, streptozotocin-induced 
diabetic mice were reported to be resistant to APAP-induced injury because of higher 
regeneration capacity and inhibiting regeneration by anti-mitotic agent (colchicine) in 
these mice resulted in increased mortality (Shankar, Vaidya et al. 2003). Furthermore, 
there are recent clinical evidences suggesting correlation of liver regeneration after 
APAP overdose with enhanced survival. Apte et al. demonstrated correlation of β-
catenin activation with higher spontaneous liver regeneration, preventing liver 
transplantation in patients (Apte, Singh et al. 2009). Another report indicated association 
of α-feto protein (marker of liver regeneration) with better survival rate in patients with 
APAP-induced ALF (Schmidt and Dalhoff 2005). All these data indicate that stimulating 
liver regeneration in APAP-induced ALF patients is a plausible therapeutic option. 
1.4 MECHANISMS OF LIVER REGENERATION AFTER APAP-INDUCED 
HEPATOTOXICITY   
In order to develop regenerative therapy for APAP-induced ALF, we should first 
understand the mechanisms of liver regeneration after APAP-induced ALF. These 
mechanisms can be different from most widely studied PH model based on the fact that 
APAP-injury is mechanistically different from PH (Table 1). APAP injury involves 
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necrosis and widespread inflammation which is minimal in PH (Michalopoulos 2010, 
Jaeschke, Williams et al. 2012). Furthermore, liver regeneration is synchronous in case 
of PH and involves proliferation of virtually all the remaining hepatocytes. In contrast, in 
case of APAP injury mostly cells around necrotic zone proliferate (Bajt, Knight et al. 
2003, Michalopoulos 2007). Although, APAP-induced liver injury is clinically significant 
model for ALF, mechanisms of liver regeneration after APAP-induced hepatotoxicity are 
highly underexplored compared to mostly commonly studied PH model of liver 
regeneration.  Following part of this section reviews some of the studies, which 
investigated mechanisms of liver regeneration after APAP-induced liver injury. 
Table 1. Differences between liver regeneration after partial hepatectomy and acute 
liver injury 
Features Partial Hepatectomy Acute Liver Injury 
Starting point A known starting point (time of 
surgery)  
Extended process with undefined 
starting point 
Location All hepatocytes in the 
remaining lobes  
Mostly areas surrounding  the 
necrotic zones 
Cell cycle Synchronous Unsynchronized 
Inflammation Not significant Extensive 
Injury Moderate Extensive (dose-dependent) 
 
Role of Cytokines: As mentioned previously, activation of cytokine pathways (IL-
6/STAT-3 and TNF-α/NF-κB) is considered as important “priming event” that contribute 
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to initiation of early stages of liver regeneration after PH (Fausto 2000). There are some 
evidences indicating role of these cytokines pathways in liver regeneration after APAP-
induced liver injury as well. TNF-α-mediated proliferative signaling in hepatocytes is 
majorly mediated by TNF receptor 1 (TNFR1). Two independent studies demonstrated 
that deletion of TNFR1 impaired liver regeneration after APAP overdose in mice (Chiu, 
Gardner et al. 2003, James, Kurten et al. 2005). TNFR1 KO mice were found to be 
more susceptible to APAP toxicity in one of these studies (Chiu, Gardner et al. 2003). 
Thus, inhibitory effects on liver regeneration by TNFR1 deletion could be mediated 
secondary to exaggerated injury. TNF-α binding to its receptor ultimately results in 
stabilization and nuclear translocation of transcription factor NF-κB. Previous reports 
showed increased hepatic TNF-α concentrations and NF-κB DNA binding after APAP 
treatment, which were correlated positively with increased cyclin D1 protein expression 
and liver regeneration in mice (Yang, Miki et al. 2009, Yang, Zhang et al. 2011, Yang, 
Zhang et al. 2012).  In contrast, decreased serum TNF-α concentration, NF-κB DNA 
binding along decreased expression of cyclin D1 were reported following interventions 
that impaired liver regeneration after APAP-induced liver injury (Yang, Miki et al. 2009, 
Yang, Zou et al. 2012). 
Similar evidences implicating role of IL6/STAT3 signaling in regeneration after APAP-
induced liver injury have been reported.  IL6 levels in liver and serum are reported to be 
increased after APAP overdose in mice (Bajt, Knight et al. 2003, James, McCullough et 
al. 2003, Masubuchi, Bourdi et al. 2003). Further, IL6-KO mice were reported to have 
impaired liver regeneration after APAP toxicity without any alteration of initial liver injury. 
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Impaired liver regeneration in IL6-KO was associated with prolonged elevation of AST 
levels (James, Lamps et al. 2003). Pretreatment with IL-6 in these KO mice resulted in 
restoration of liver regeneration parameters along with decrease in AST levels, 
indicating role of IL-6 in liver regeneration and recovery after APAP-induced 
hepatotoxicity (James, Lamps et al. 2003). IL-6 binding to its receptor at cellular 
membrane leads to phosphorylation and nuclear translocation of STAT-3, which 
ultimately results in transcription of its target genes. Impaired liver regeneration in 
TNFR1 KO mice was associated with delayed phosphorylation of STAT-3 suggesting 
cross-talk of TNF-α/NF-κB and IL-6/STAT-3 signaling in liver regeneration after APAP-
induced liver injury, as known to exist in case of PH model (Chiu, Gardner et al. 2003).  
Role of growth factors: Growth factors such as EGFR ligands and HGF are considered 
direct mitogens for hepatocytes and are critical for liver regeneration after PH. In fact, 
EGFR ligands (such as EGF and TGFα) and HGF are the only known direct mitogens 
for hepatocytes (Michalopoulos 2007). EGFR ligands and HGF act primarily through 
activation of EGF receptor (EGFR) and c-Met receptor, respectively. Genetic ablation or 
siRNA-mediated downregulation of cMet caused almost complete blockage of liver 
regeneration after PH highlighting importance of this pathway in liver regeneration 
(Michalopoulos 2007). Although, growth factors signaling plays central role in liver 
regeneration and hepatocyte proliferation after PH, their role in liver regeneration after 
APAP-induced liver injury is relatively unknown. In a study using sixty-two beagle dogs, 
administration of hepatic stimulatory substance alone or in combination with TGF-α, 
insulin-like growth factor II and insulin did not affect survival or liver regeneration after 
lethal dose (LD70) of APAP (Francavilla, Azzarone et al. 1993). In another study, 
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plasma HGF levels were found to be strikingly elevated in APAP-induced ALF patients. 
However, plasma HGF levels were significantly higher in non-survivors compared to 
survivors after APAP-induced ALF (Hughes, Zhang et al. 1994).  These evidences 
indicate that stimulation with additional direct mitogens after APAP-induced ALF may 
not be beneficial. However, further mechanistic studies are required to delineate 
potential role of these direct mitogens in hepatocyte proliferation after APAP-induced 
ALF. 
Vascular endothelial growth factor (VEGF) is a mitogen for endothelial cells and is 
known to play an important role in angiogenesis during liver regeneration after PH. 
Further, it can indirectly cause hepatocyte proliferation via production of HGF from 
endothelial cells (Michalopoulos 2007).  Several reports have demonstrated important 
role of VEGF and its receptor VEGFR in liver regeneration after APAP-induced 
hepatotoxicity.  Hepatic VEGF levels and expression of its receptors (VEGFR1, VEGFR 
2, and VEGFR 3) increases after APAP overdose in mice and rats (Donahower, 
McCullough et al. 2006, Papastefanou, Bozas et al. 2007, Kato, Ito et al. 2011). 
Whereas, treatment with VEGFR inhibitor in mice impaired hepatocyte proliferation 
(Donahower, McCullough et al. 2006), administration of human recombinant VEGF 
increased hepatocyte regeneration after APAP overdose in mice, without altering initial 
hepatotoxicity (Donahower, McCullough et al. 2010). Further, VEGFR1 KO mice 
exhibited impaired restoration of microvasculature, diminished hepatocyte proliferation 
and expression of growth factors such as HGF and FGF, associated with decreased 
survival after APAP overdose (Kato, Ito et al. 2011). 
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Role of progenitor cells: Role of progenitor cells in liver regeneration has been a topic of 
intense debate. In most of the scenarios, proliferation of remnant hepatocytes to 
produce new hepatocytes is sufficient for liver regeneration. However, in case of severe 
hepatic injury where hepatocyte proliferation is inhibited, cells of biliary ductular origin 
(specifically terminal bile ductules called canals of Herring) can give rise to bipotent 
progenitor cells (known as the oval cells). These cells have ability to differentiate into 
hepatocytes restoring liver regeneration (Michalopoulos 2011). A dose and time-
dependent bi-phasic oval cell reaction was also reported after administration of sub-
lethal doses of APAP in mice, which was largely restricted to smallest portal tracts 
(Kofman, Morgan et al. 2005). Interestingly, the time-course of oval cell reaction in mice 
was closely correlated to previously documented temporal changes in serum stem cell 
factor (SCF) after APAP-induced liver injury, suggesting potential role of SCF in 
progenitor cell activation (Simpson, Hogaboam et al. 2003, Kofman, Morgan et al. 
2005).  Another study reported increased expression of SCF and its receptor c-kit 
(progenitor cell marker) in liver after APAP overdose in mice (Hu and Colletti 2008). 
While, mice treated with anti-SCF antibody and SCF-deficient mice exhibited increased 
mortality, treatment with exogenous SCF increased hepatocyte proliferation and 
improved survival after APAP-induced liver injury (Simpson, Hogaboam et al. 2003, Hu 
and Colletti 2008). Further, recent studies have suggested hepatic stellate cells as ‘stem 
cell niche’ for hepatic progenitor cells. Depletion of activated stellate cells using gliotoxin 
resulted in impaired liver regeneration after APAP overdose in mice, which was 
associated with decreased oval cell reaction (Shen, Chang et al. 2011). Similarly, 
progenitor cell response was also observed in APAP-induced ALF patients with severe 
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liver necrosis (Theise, Saxena et al. 1999). Furthermore, α-feto protein (marker of fetal 
phenotype and progenitor cells) positive cells were found in APAP-induced ALF patients 
(Theise, Saxena et al. 1999) and serum AFP levels were correlated with better 
prognosis and survival in APAP-induced ALF patients (Schmidt and Dalhoff 2005). All 
these studies suggest potential role of progenitor cells in liver regeneration after APAP-
induced ALF, which should be explored in future for the standpoint of regenerative 
therapy and biomarker development.  
1.5 WNT/ β -CATENIN SIGNALING AND ITS ROLE IN LIVER REGENERATION 
Wnt/β-catenin signaling is known to play an important role in liver development and 
maturation (Thompson and Monga 2007). β-catenin is a transcription factor, which 
under un-stimulated state is bound to destruction complex consisting of Axin, 
Adenomatous polyposis coli (APC), Glycogen synthase kinase-3β (GSK3β) and Casein 
kinase 1 (CK1). CK1 first phosphorylates β-catenin at Ser45, which primes β-catenin. 
Primed β-catenin is recognized by GSK3β, which phosphorylates β-catenin at Thr41 
residue and subsequently at Ser33 and Ser37 residues. Phosphorylated β-catenin is 
recognized by β-TrCP (an E3 ubiquitin ligase subunit), and subsequently ubiquitinated 
and targeted for proteosomal-mediated degradation (Fig. 1.5.1) (Clevers 2006, 
Kaidanovich-Beilin and Woodgett 2011). During canonical Wnt signaling, Wnts binds to 
Frizzled (Fzd) receptor which associates with LRP 5/6 and recruits Dishevelled (Dvl), 
which leads to phosphorylation of LRP 5/6. Phospho-LRP 5/6 binds to Axin leading to 
dissociation of β-catenin destruction complex and inactivation of GSK3β. This results in 
stabilization of β-catenin and its nuclear translocation. In nucleus, β-catenin binds with T  
 





Figure 1.5.1. Schematic representation of canonical Wnt/β-catenin signaling 
pathway. Wnts binding to Frizzled receptor leads to inactivation of β-catenin destruction 
complex, hypo-phosphorylation and stabilization of β-catenin, which translocates to 
nucleus and cause transcriptional activation of its target genes (left panel). Under un-
stimulated state, β-catenin is bound by its destruction complex, which phosphorylate β-
catenin and target it for proteosomal degradation (Right panel). Adapted from 
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cell factor/lymphoid-enhancing factor (TCF/LEF) family of DNA binding proteins and 
cause transcriptional activation of its targets such as axin2, glutamine synthetase, cyclin 
D1 and lect2 (Clevers 2006, Nejak-Bowen and Monga 2011) (Fig. 1.5.1). Independent 
of Wnt signaling, β-catenin also associates with cytoplasmic domain of E-cadherin as a 
component of cell-cell adherens junction. This bound pool of β-catenin is stable and not 
available for degradation by destruction complex (Clevers 2006, Thompson and Monga 
2007).    
Previous literature suggests important role of Wnt/β-catenin signaling in liver 
regeneration after PH (Nejak-Bowen and Monga 2011). β-catenin gets activated very 
early during liver regeneration after PH in rats (Monga, Pediaditakis et al. 2001). 
Knockdown of β-catenin in rats using antisense oligonucleotide resulted in decreased 
liver regeneration (Sodhi, Micsenyi et al. 2005). Further, in two independent studies, 
liver-specific deletion of β-catenin in mice caused delayed liver regeneration, which was 
correlated with decreased cyclin D1 induction (Tan, Behari et al. 2006, Sekine, 
Gutierrez et al. 2007). In contrast, mice over-expressing Ser45 mutated β-catenin 
displayed accelerated liver regeneration after PH, which was correlated with increased 
expression of cyclin D1. Furthermore, direct gene delivery of Wnt-1 in mice showed 
similar increase in hepatocyte proliferation (Nejak-Bowen, Thompson et al. 2010). β-
catenin activation has also been observed during liver regeneration following treatment 
with sublethal dose of APAP in mice (Apte, Singh et al. 2009). Activation was 
specifically observed in the areas surrounding the centrilobular necrotic areas, which 
was correlated with increased cyclin D1 expression and liver regeneration. Liver specific 
deletion of β-catenin in mice compromised expression of enzymes (CYP2E1 and 
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CYP1A2) involved in metabolic activation of APAP resulting in attenuated APAP toxicity. 
In order to study direct role of β-catenin on liver regeneration after APAP-induced liver 
injury, CYPs were induced in mice and equitoxic doses were compared in β-catenin KO 
and control mice. In this equitoxic dose study, liver regeneration was found to be 
decreased in β-catenin KO mice suggesting role of β-catenin in liver regeneration after 
APAP-induced ALF (Apte, Singh et al. 2009). Moreover, analysis of liver samples from 
APAP-induced ALF patients showed correlation of β-catenin activation with higher 
spontaneous liver regeneration, avoiding need for liver transplantation (Apte, Singh et 
al. 2009). Further investigation in clean experimental models will help to confirm role of 
β-catenin in liver regeneration after APAP-induced liver injury. 
1.6 GLYCOGEN SYNTHASE KINASE-3 (GSK3) SIGNALING AND ITS ROLE IN 
LIVER REGENERATION 
Glycogen synthase kinase-3 (GSK3) is a ubiquitously expressed serine/threonine 
protein kinase, which is constitutively active in cells under resting state and primarily 
regulated by inactivation. In mammals, GSK-3 exists in two isoforms GSK-3α and GSK-
3β which share 98% sequence homology in kinase domain leading to almost redundant 
functionality (Kaidanovich-Beilin and Woodgett 2011). GSK3 lie downstream of number 
of major signaling pathways including growth factors, insulin and Wnt signaling, which 
negatively regulate GSK3 activity. GSK3 activity is primarily regulated by 
phosphorylated-mediated inactivation, but other methods of inactivation such as 
sequestration and subcellular localization are also known (Jope and Johnson 2004). 
Initially discovered to regulate glycogen synthase, GSK3 is now known to regulate a 
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wide spectrum of proteins and affect a number of cellular functionalities including 
proliferation, differentiation and survival (Jope and Johnson 2004). GSK3 functions by 
phosphorylation-mediated inactivation/ degradation of its substrates. As described in 
previous section, GSK3 causes phosphorylation mediated targeting of β-catenin for 
proteosomal degradation, thus negatively regulating β-catenin signaling (Doble and 
Woodgett 2003). Apart from β-catenin, GSK3 can regulate many other cell proliferation 
mediators such as Cyclin D1, c-Myc, c-Jun, and eIF2B (Sutherland 2011). For instance, 
GSK3β can directly regulate Cyclin D1 protein by its phosphorylation, proteolysis and 
decreased nuclear localization (Diehl, Cheng et al. 1998).  
Role of GSK3 in liver regeneration has not been as extensively studied as compared to 
β-catenin. GSK3 inhibitor had reported to induce in-vitro expansion of mice primary 
hepatocytes (Ito, Kamiya et al. 2012). Further, inhibition of GSK3 facilitated survival 
signaling in primary human hepatocytes via activation of β-catenin (Gotschel, Kern et al. 
2008). Moreover, GSK3 negatively regulates β-catenin, which is known to play an 
important role in liver regeneration. Counterintuitively, several studies indicate that 
GSK3 may play a pro-regenerative role after PH (Chen, Yang et al. 2007, Jin, Wang et 
al. 2009, Sekiya and Suzuki 2011). Treatment with GSK3 inhibitor or siRNA mediated 
downregulation of GSK3 has reported to impair liver regeneration in mice and rats after 
PH (Chen, Yang et al. 2007, Jin, Wang et al. 2009, Sekiya and Suzuki 2011). However, 
role of GSK3 in compensatory liver regeneration after APAP-induced liver injury is not 
known and can be different from PH model based on mechanistic difference between 
these models. Nevertheless, increased inactivation of GSK3β (Ser9 phosphorylation) 
was observed during regenerative phase after APAP-induced liver injury in mice, which 
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was correlated with increased liver regeneration (Apte, Singh et al. 2009). Silencing of 
GSK3β resulted in inhibition of APAP-induced injury, but this was attributed to role of 
GSK3β in initiation of APAP toxicity. However, increased Ser9 phosphorylation of 
GSK3β (inactive form) was observed after APAP administration in this study as well 
(Shinohara, Ybanez et al. 2010). This inactivation of GSK3β may have role to play in 
liver regenerative, which was not investigated in this report. Thus, further investigations 
are required to establish role GSK3 in compensatory liver regeneration after APAP-
induced liver injury.  
1.7 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND ITS ROLE IN LIVER 
REGENERATION 
Epidermal growth factor receptor (EGFR) or ErbB-1 is a prototypical tyrosine kinase 
receptor of the ErbB family, which is highly expressed in liver and known to be involved 
in hepatocytes proliferation, liver regeneration and hepatocellular carcinogenesis 
(Michalopoulos and DeFrances 1997, Carver, Stevenson et al. 2002, Michalopoulos 
and Khan 2005). Other ErbB family members include ErbB-2, ErbB-3 and ErbB-4.  
ErbB-2 does not have any known ligand and its expression greatly decreases in adult 
liver; ErbB-3 is present in adult liver but lacks intrinsic kinase activity; ErbB-4 is not 
expressed in adult or embryonic liver (Carver, Stevenson et al. 2002, Michalopoulos 
and Khan 2005). EGFR is a cell surface receptor with an extracellular ligand-binding 
domain, a transmembrane domain and a cytoplasmic domain with tyrosine kinase 
activity. EGFR can be activated by variety of extracellular ligands, including EGF, 
transforming growth factor alpha (TGF-α), heparin-binding EGF (HB-EGF) and 
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amphiregulin. Ligand binding results in dimerization of EGFR and activation of its 
intrinsic tyrosine kinase domain. This subsequently results in auto-phosphorylation of 
tyrosine residues in the cytoplasmic domain. These resultant phosphorylation residues 
act as docking sites for multiple proteins leading to activation of wide spectrum of cell 
signaling pathways (Normanno, De Luca et al. 2006). 
Apart from HGF, EGFR ligands are the only known direct mitogens which can cause 
hepatocyte proliferation in serum free medium, highlighting an important role of EGFR in 
hepatocyte proliferation (Michalopoulos 2007). In vivo administration of EGFR ligands 
such as EGF and TGF-α also lead to hepatocyte proliferation along with increased liver 
size (Bucher, Patel et al. 1977) . EGFR is activated very rapidly after 2/3rd liver 
resection i.e. partial hepatectomy (PH) and is known to play an important role in 
promoting timely liver regeneration (Michalopoulos and Khan 2005, Michalopoulos 
2007, Fausto, Campbell et al. 2012). Genetic deletion of EGFR in mouse liver or shRNA 
mediated downregulation of EGFR in rats resulted in impaired and delayed liver 
regeneration after PH, but final recovery of liver mass was not affected due to 
compensatory mechanisms (Natarajan, Wagner et al. 2007, Paranjpe, Bowen et al. 
2010). In another study, hepatocyte specific deletion of EGFR in mice produced weaker 
impairment on liver regeneration after PH, but no alteration was observed on liver 
regeneration after CCl4-induced liver necrosis (Scheving, Zhang et al. 2015). Mice 
deficient in EGFR ligands - amphiregulin and HB-EGF – or sialadenectomized mice that 
have lower level of serum EGF displayed deficient liver regeneration. Further, 
overexpression or injection of HB-EGF in rodents increased liver regeneration 
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(Michalopoulos and Khan 2005, Michalopoulos 2007, Fausto, Campbell et al. 2012). 
Role of EGFR in liver regeneration after APAP-induced liver injury is entirely unknown. 
1.8 STATEMENT OF PURPOSE 
Current treatment options for APAP overdose patients are very limited and warrant 
development of novel therapeutic strategies. Recent studies suggest that liver 
regeneration is a critical determinant of final recovery and survival following APAP 
overdose (Hu and Colletti 2008, Apte, Singh et al. 2009, Donahower, McCullough et al. 
2010). Thus, stimulating liver regeneration in patients of APAP-induced ALF holds a 
great therapeutic potential. Although mechanisms of liver injury after APAP overdose 
have been extensively studied, our knowledge regarding mechanisms of compensatory 
liver regeneration following APAP-induced injury is extremely limited, hindering 
development of novel regenerative therapies for ALF.  Our long-term goal is to develop 
regenerative therapies based on stimulation of liver regeneration for APAP-induced 
ALF. The objective of this dissertation work was to investigate mechanisms of liver 
regeneration and identify targets to stimulate liver regeneration after APAP-induced liver 
injury. We used an incremental dose model to delineate the mechanisms of liver 
regeneration following APAP-induced ALF with hypothesis that liver regeneration should 
remain intact after lower dose, but impaired at higher dose. Thus, differential regulation 
of regenerative pathways after APAP-induced toxicity could be analyzed and potential 
targets to stimulate regeneration after APAP overdose could be identified. Further, 
based on previous literature, we hypothesized that β-catenin and GSK3 play important 
role in liver regeneration such that stimulation of β-catenin or inhibition of GSK3 after 
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APAP-induced ALF would result in improved liver regeneration. This was investigated 
by overexpression β-catenin and pharmacological inhibition of GSK3 in mice. Lastly, 
EGFR is known to play important role in liver regeneration after liver resection but its 
role liver regeneration after APAP-induced liver injury is completely unexplored. Thus, 
role of EGFR in liver regeneration after APAP-induced liver injury was investigated 
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Acetaminophen (APAP) overdose results in acute liver failure (ALF) and has very 
limited treatment options. Previous studies show that stimulating liver regeneration is 
critical for survival after APAP overdose but the mechanisms remain unclear. In this 
study, we identified major signaling pathways involved in liver regeneration following 
APAP-induced acute liver injury using a novel incremental dose model. Liver injury and 
regeneration were studied in C57BL/6 mice treated with either 300 mg/kg (APAP300) or 
600 mg/kg (APAP600) APAP. Mice treated with APAP300 developed extensive liver 
injury and robust liver regeneration. In contrast, APAP600 treated mice exhibited 
significant liver injury but substantial inhibition of liver regeneration resulting in sustained 
injury and decreased survival. The inhibition of liver regeneration in APAP600 group 
was associated with cell cycle arrest, decreased cyclin D1 expression and sustained 
p21 expression. Several known regenerative pathways including IL-6/STAT-3, EGFR/c-
Met/MAPK pathway were activated even at APAP600 where regeneration was inhibited. 
However, canonical Wnt/β-catenin and NF-κB pathways were activated only in 
APAP300 treated mice where liver regeneration was stimulated. Next, we investigated 
role of Wnt/β-catenin in further detail. ChIP analysis revealed increased binding of β-
catenin to cyclin D1 promoter specifically at APAP300 correlating with higher cyclin D1 
induction. Furthermore, overexpression of a stable form of β-catenin (S45D) in mice 
resulted in increased hepatocyte proliferation and improved liver regeneration following 
APAP overdose. Improved liver regeneration in S45D was associated with increased 
expression of Cyclin D1. Taken together, our incremental dose model has identified 
differential role of several signaling pathways in liver regeneration after APAP overdose 
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Acetaminophen (APAP) is one of the most widely used over-the-counter 
analgesic and anti-pyretic drug in the world. APAP is safe at therapeutic doses but 
overdose can cause acute liver failure (ALF). In fact, APAP overdose is associated with 
more than 78,000 emergency room visits and 33,000 hospitalizations every year in the 
US (Budnitz, Lovegrove et al. 2011, Manthripragada, Zhou et al. 2011). The only 
pharmacological intervention, at present, is N-acetylcysteine (precursor of glutathione), 
which is successful only if given within few hours after APAP overdose (Athuraliya and 
Jones 2009). Ultimate option is liver transplantation, which is complicated by issues 
such as donor availability, long term immunosuppression and exorbitant costs (Keeffe 
2001). 
Previous studies suggest that liver regeneration following APAP overdose plays 
a critical role in determination of outcome of injury (Schmidt and Dalhoff 2005, Hu and 
Colletti 2008, Apte, Singh et al. 2009, Donahower, McCullough et al. 2010). α-Feto 
protein, a marker of liver regeneration, was found to be associated with better survival 
rate in patients with APAP-induced ALF (Schmidt and Dalhoff 2005). Several other 
studies in animal models suggest that timely stimulation of liver regeneration, such as 
with stem cell factor (Hu and Colletti 2008) and VEGF (Donahower, McCullough et al. 
2010), improves survival after APAP overdose in mice. These studies highlight 
stimulating liver regeneration in APAP-induced ALF patients as a plausible therapeutic 
option. However, the mechanisms of liver regeneration after APAP-induced ALF are not 
well known. Whereas liver regeneration has been extensively studied in past 
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(Michalopoulos 2007), most of the studies are based on partial hepatectomy (PH) 
model, a mechanistically different model from APAP-induced ALF. 
Data on hepatotoxicants, in general, suggest that liver regeneration follows the 
principles of dose-response(Mehendale 2005). Studies indicate that liver regeneration 
following toxic injury to liver increases proportionately to injury but only up-to a threshold 
dose. Doses higher than the threshold dose actually inhibit liver regeneration resulting 
in progression of injury to acute liver failure and death (Mangipudy, Chanda et al. 1995, 
Anand, Murthy et al. 2003, Mehendale 2005). These studies have suggested that at 
higher doses regeneration is inhibited due to blockade in critical pro-regenerative 
signaling pathways (Mangipudy, Chanda et al. 1995, Apte, Limaye et al. 2003, 
Mehendale 2005). Based on this principle, we developed a novel incremental dose 
model to delineate the mechanisms of liver regeneration following APAP-induced acute 
liver injury (ALI). We used two doses of APAP, a lower dose (300 mg/kg) following 
which liver regeneration is intact and a higher dose (600 mg/kg) after which liver 
regeneration is inhibited. We performed a comprehensive analysis of several signaling 
pathways known to be involved in liver regeneration and identified pathways, which are 
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2.3 MATERIALS AND METHODS 
Animals, Treatment and Tissue Harvesting 
Two-month-old male C57BL/6 mice purchased from Jackson Laboratories were used in 
these studies. Mice overexpressing stable form of β-catenin, where Serine 45 is 
mutated to Aspartic Acid (S45D) have been described before (Nejak-Bowen, Thompson 
et al. 2010). Details of generation and characterization of these mice have been 
published previously (Nejak-Bowen, Thompson et al. 2010). All animals were housed in 
Association for Assessment and Accreditation of Laboratory Animal Care-accredited 
facilities at the University of Kansas Medical Center under a standard 12-hr light/dark 
cycle with access to chow and water ad libitum. The Institutional Animal Care and Use 
Committee at University of Kansas Medical Center approved all studies. Mice were 
fasted 12 hr before administration of APAP.  APAP was dissolved in warm 0.9% saline 
and mice were treated with either 300 or 600 mg/kg APAP, intraperitoneally (i.p.). Food 
was returned to the mice after APAP treatment. Mice (n = 3 to 7) were sacrificed at 0, 
0.5, 1, 3, 6, 12, 24, 48, 72 and 96 hr following APAP treatment by cervical dislocation 
under isofluorane anesthesia, and blood and livers were collected. The S45D and 
respective wild-type (WT) littermates were treated with either 300 or 600 mg/kg APAP 
and sacrificed at 6 and 24 hours (APAP300 study) or 24 and 48 hours (APAP600 study) 
after APAP administration, followed by blood and liver collection. Serum samples were 
obtained from the blood and used for analysis of alanine aminotransferase (ALT) activity 
using commercially available kits (ThermoFisher Scientific, Pittsburgh PA). Liver 
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sections, nuclear and cytoplasmic protein extracts were prepared as described 
previously (Wolfe, Thomas et al. 2011).  
Antibodies 
All primary antibodies obtained from Cell Signaling Technologies (Danvers, MA) for 
Western blot analysis.  Active β-catenin antibody was obtained from EMD Millipore 
Corporation (Billerica, MA). All secondary antibodies used for Western blot analysis 
were obtained from Cell Signaling Technologies.  Biotinylated secondary antibodies for 
immunohistochemistry were purchased from Jackson Immunoresearch (West Grove, 
PA).  
Protein Isolation and Western Blotting  
Protein estimation and western blot analysis was performed using pooled samples of 
protein extracts prepared from frozen liver tissues as previously published without any 
modifications (Wolfe, Thomas et al. 2011).  
PCNA Immunohistochemistry 
Paraffin-embedded liver sections (4 µm thick) were used for immunohistochemical 
detection of PCNA as described before (Wolfe, Thomas et al. 2011).  
Real Time PCR 
Total RNA was isolated from APAP300 and APAP600 livers using Trizol method 
according to the manufacturer’s protocol (Sigma, St. Louis, MO) and converted to cDNA 
as previously described (Apte, Singh et al. 2009). mRNA levels of various genes were 
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determined using Real Time PCR analysis using commercially available TaqMan Gene 
Expression Assays (Life Technologies previously known as Applied Biosystems, 
Carlsbad, CA) on the Applied Biosystems Prism 7300 Real-time PCR Instrument 
according to manufacturer’s protocol. Rplp0 gene expression in the same samples was 
used for data normalization and data was expressed as fold change compared to 0 hr. 
Chromatin Immunoprecipitation (ChIP) 
ChIP was done using whole liver tissue from APAP300 and APAP600 animals for 12 hr 
time point as described previously (Walesky, Gunewardena et al. 2013). Chromatin was 
isolated using approximately 200 mg of frozen liver tissue from three mice of each 
group. Isolated chromatin was then incubated with either no antibody, β-catenin (5 μg; 
BD transduction, Catalogue # 610154) or p65 (5 μg; Cell Signaling, Catalogue # 8242) 
antibodies for immunoprecipitation. Real-time PCR analysis was done using primers 
designed to cover known p65 and β-catenin binding sites on Ccnd1 promoter. Data was 
normalized with input DNA and represented as fold enrichment with respect to no 
antibody control.  Primers sequence: Forward – 5’-GCAGGACTTTGCAACTTCAAC-3’; 
Reverse – 5’-TTTCTCTGCCCGGCTTTG-3’ 
Statistical Analysis 
Data presented in the form of bar/line graphs show mean ± SEM. Significant difference 
between groups was determined using Student’s T-test. Difference between groups was 
considered statistically significant at P<0.05. Statistically significant difference was 
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represented as * in graphs when compared between the two doses and represented as 
# when compared with respect to basal levels (0 hr) wherever specified. 
 
2.4 RESULTS 
Sustained injury and inhibited recovery after higher dose of APAP 
We compared liver injury at the two doses of APAP (APAP300 and APAP600) 
over the time-course of 0 to 96 hr by studying serum ALT and histopathological analysis 
of liver sections (scoring sections for percent necrosis) (Fig. 2.4.1A, B and C). Liver 
injury increased after APAP treatment and peaked at 12 hr after treatment in both the 
doses. Liver injury was characterized by necrosis in the centrilobular region, hallmark of 
APAP toxicity. Interestingly, there was no significant difference in injury up to 24 hr in 
both the groups except area of necrosis was significantly higher at 12 hr in APAP600 
compared to APAP300 group (Fig. 2.4.1C). Overall trend showed moderately higher 
injury in APAP600 group up to 24 hr. However, there was marked difference in 
progression of injury at later time points. APAP300 showed slight regression of injury at 
48 hr and complete recovery at 72 and 96 hr as evidenced by decreased serum ALT 
levels, complete recovery from necrosis and 100% survival. In contrast, approximately 
25% animals died at various time points from 48 to 96 hr in APAP600 group (Fig. 
2.4.1B). Remaining animals showed sustained injury and were not recovered up to 96 
hr. Injury was strikingly higher at 72 and 96 hr in APAP600 group compared to 
APAP300 group.  
 





Figure 2.4.1. Sustained liver injury and inhibited recovery after higher dose of APAP. (A) 
Representative photomicrographs of H&E stained liver sections with necrotic area outlined (CV 
denotes central vein and PT denotes portal triad) (B) Bar graph showing serum ALT levels with 
percent survival specified over bars at time points where any mortality was observed. (C) Bar 
graph showing percent necrosis area based on H&E stained liver sections.  All samples were 
collected from mice (n = 3-7) treated with either 300 or 600 mg/kg APAP at various time points 
up-to 96 hr after APAP treatment. * indicate significant difference between two doses at p<0.05 
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Inhibited liver regeneration and cell-cycle arrest correlated with sustained injury 
and inhibited recovery at higher dose 
Next, we studied liver regeneration at the two doses of APAP using PCNA 
immunohistochemistry (Fig. 2.4.2A). Quantification of total PCNA positive cells (Fig. 
2.4.2B) showed evidence of a few cells entering cell cycle as early as 3 hr in APAP300, 
but robust proliferation response with dramatic increase in PCNA positive cells was 
observed only from 12 hr after APAP treatment specifically around the necrotic areas. 
PCNA positive cells remains elevated up to 48 hr and then progressively decreased at 
72 and 96 hr. In contrast, APAP600 showed almost no PCNA positive cells up to 24 hr 
after APAP administration. PCNA positive cells started appearing at much delayed time 
point of 48 hr onwards in APAP600 group and were significantly lower compared to 
APAP300 group. The PCNA data were corroborated by Ki-67 immunofluorescence 
staining (Fig. 2.4.3). Overall, there was significantly delayed and attenuated liver 
regeneration in APAP600 group which correlated with sustained injury, delayed 
recovery and decreased survival at the higher dose.  
Interestingly, even at the time point of peak injury (12 hr after APAP treatment) at 
higher dose, more than 50% of hepatocytes were still intact as demonstrated by 
necrosis scoring. This suggests that marked decrease in regeneration in the APAP600 
dose is not due to lack of viable hepatocyte in the higher dose. This was further 
confirmed by HNF4α staining as a marker of intact hepatocytes (Fig. 2.4.4). In fact, 
overall cellular death was not strikingly different at the two doses at early time points 
where regeneration was initiated at lower dose. Further, closer look at individual animal 
data revealed even though there was no difference in liver injury in some animals  
 




Figure 2.4.2. Inhibition of liver regeneration following higher dose of APAP. (A) Representative 
photomicrographs of PCNA stained liver sections. Insets show cells in specific phase of cell cycle as 
denoted by arrows, with arrows pointing out different phases of cell cycle. G0 cells: blue nuclear staining; 
G1 cells: light brown nuclear staining; S phase cells: deep brown nuclear staining; G2 cells: diffused 
brown cytoplasmic staining; M phase cells: deep-blue chromosomal staining. (B) Line graph showing total 
number of PCNA positive cells per five high power (40x) fields. Line graphs showing total number of cells 
in (C) G1, (D) S, (E) G2 and (F) M phases per five high power (40x) fields demonstrating cell cycle 
progression. All samples were collected from mice (n = 3-5) treated with either 300 or 600 mg/kg APAP 
over a time course of 0 to 96 hr after APAP treatment. CV denotes central vein and PT denotes portal 
triad. * indicate significant difference between two doses at p<0.05 
 





Figure 2.4.3. Inhibition of liver regeneration following higher dose of APAP. 
Representative photomicrographs showing Ki-67 immuno-fluorescence performed on frozen 
liver sections of mice treated with either 300 or 600 mg/kg APAP and scarified at 24 hr after 
APAP treatment.  (Ki-67: Red; DAPI: Blue; Merge: Pink) 
 
 




Figure 2.4.4. HNF4α staining showing intact hepatocytes following higher dose of APAP. 
HNF4α immunohistochemistry on paraffin-embedded liver sections from mice treated with 600 
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between groups but there was striking difference in regenerative response (data not 
shown).   
Next, we quantified cells in specific cell cycle phase by studying PCNA stained sections 
in detail to further look into progression of cell cycle (Fig 2.4.2C-F). In APAP300 group, 
cells started entering cell cycle at 12 hr with numerous cells entering into G1 phase from 
G0 phase. At 24 hr, most of the cells were still in G1 phase with many cells progressed to 
S phase. Majority of the cells progressed to S phase at 48 hr and further to G2 phase by 
72 hr. Mitoses were evident between 48 to 96 hr. By 96 hr, majority of cells returned to 
quiescent state. In contrast, in APAP600 group, almost all the cells stayed in G0 phase 
up to 24 hr. A few cells started entering G1 phase only at much delayed time point of 48 
hr and further these cells do not progress through cell cycle at later time points and 
remain arrested at G1 phase. No mitotic activity was observed at any time points in 
APAP600 group. These results suggest that inhibition of entry into cell cycle and early 
cell cycle arrest in the remaining viable hepatocytes at higher dose is the reason for 
inhibited liver regeneration rather than mere higher cell death. 
Cell cycle regulators correlated with arrested cell cycle and inhibited liver 
regeneration at higher dose 
We further studied expression of various core cell cycle proteins, which regulate 
cell cycle entry. We first determined Cyclin D1 levels, induction of which is the critical 
step which is required by hepatocytes for progressing through G1 phase and committing 
to DNA replication (Fausto 2000). There was an early 2-fold induction of Cyclin D1 
mRNA at 3 hr followed by a sharp peak (6-fold induction) at 12 hr specifically in 
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APAP300 group correlating with time of onset of regenerative phase. Cyclin D1 mRNA 
level rapidly declined at 24 hr to around 2.5-fold and reached to basal level by 96 hr. In 
contrast, Cyclin D1 mRNA did not increase significantly in APAP600 group at any time 
point but showed slight induction in some animals at much delayed time points of 48 
and 96 hr (Fig. 2.4.5A). Moreover, we observed significant decrease in Cyclin D1 mRNA 
levels at 6 hr compared to basal levels in APAP600 group suggesting active inhibition of 
cell cycle. Western blot analysis further corroborated mRNA data with early and overall 
much higher increase in Cyclin D1 protein only in APAP300 dose correlating with PCNA 
protein expression (Fig. 2.4.5B). Cyclin D1 binds to CDK4 and this complex in-turn 
causes phosphorylation and inactivation of Rb, which ultimately leads to transcription of 
many cell cycle genes (Fausto 2000). CDK4 protein and phosphorylation of Rb followed 
trend similar to Cyclin D1 expression (Fig. 2.4.5B).  
We further analyzed dynamics of cyclin dependent kinase inhibitors, p21 and p27 
to elucidate if active cell cycle inhibition is involved at higher dose (Fig. 2.4.5C and D). 
Interestingly, p21 mRNA was markedly induced at both the doses as early as 3 hr after 
APAP. However, induction was much higher and sustained up to 96 hr at higher dose 
but decreased remarkably after 24 hr at lower dose (Fig 2.4.5C). Protein expression of 
p21 also displayed similar trend. p27 protein also showed moderate induction at both 
doses showing pattern similar to p21 with notable higher expression at 6 hr after APAP 
treatment at higher dose, the time point preceding onset of normal liver regeneration 
response in regenerative dose (Fig 2.4.5D). These data suggest that active cell cycle 
inhibition is involved at higher dose of APAP where liver regeneration is inhibited.  
 




Figure 2.4.5. Cell cycle regulators correlated with inhibited liver regeneration at higher 
dose. (A) Cyclin D1 mRNA expression (B) Cyclin D1, CDK4, phospho-Rb, PCNA, (C) p21 
mRNA and (D) p21 and p27 protein in liver of mice treated with either 300 or 600 mg/kg APAP. 
All samples were collected over a time course of 0 to 96 hr after APAP treatment (n = 3-5). * 
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Overall, early and robust induction of cyclin D1 at lower dose resulted in timely liver 
regeneration and recovery. Inhibition of such robust and timely response and sustained 
activation of cell cycle inhibitors at higher dose correlated with cell cycle arrest, inhibited 
liver regeneration, progression of injury and decreased survival. Next, we studied major 
upstream pathways, which are known to induce cyclin D1 and stimulate liver 
regeneration. For these studies, based on the time course of regenerative response, we 
focused on time points up to 24 hr after APAP treatment considering importance of early 
regenerative response for successful recovery.  
Growth factor signaling via EGFR and c-Met and MAPKs signaling remains highly 
activated following high dose of APAP 
Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are 
considered the primary mitogens for hepatocytes and are critical for liver regeneration 
after PH (Michalopoulos 2007). EGF and HGF act primarily through activation of EGF 
receptor (EGFR) and c-Met receptor, respectively (Michalopoulos 2007).  This leads to, 
among others, activation of MAPK signaling culminating in cell proliferation. However, 
importance of these growth factors in liver regeneration following APAP-induced ALI is 
not known. We found that the protein expression of EGFR and c-Met was increased at 
both the doses (Fig 2.4.6A). To determine activation status of these receptors, we 
investigated the expression of phosphorylated forms of EGFR and c-Met. There was 
remarkable activation of EGFR as early as 0.5 hr after APAP300 treatment attaining 
peak at 6 hr, the time point preceding onset of marked liver regeneration response and  
 




Figure 2.4.6. Growth factor signaling via EGFR/ c-Met and MAPKs signaling remains 
highly activated following high dose of APAP. Western blot analysis of (A) EGFR, phospho-
EGFR (normal and high exposures), c-Met, phospho-Met, (B) total AKT, phospho-AKT, total 
p38, phospho-p38, total ERK1/2, phospho-ERK 1/2, (C) total JNK, phospho-JNK, (D) c-Jun and 
c-Fos using total liver extract of mice liver treated with either 300 or 600 mg/kg APAP. (E), (F), 
(G) and (H) Densitometric analysis showing p38, ERK 1/2, JNK and AKT activation respectively. 
All samples were collected over a time course of 0 to 24 hr after APAP treatment (n = 3-5). 
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then progressively decreased at later time points. Interestingly, similar trend was 
observed for APAP600 group with much higher and sustained response in dose-
dependent manner (Fig 2.4.6A). Similar results were observed for c-Met activation for 
which we found marked phosphorylation only at 6 hr after APAP300 treatment but much 
higher and sustained phosphorylation after APAP600 treatment starting as early as 3 hr 
and maintained till 12 hr (Fig 2.4.6A).  Further studies on downstream MAPK signaling 
revealed that AKT, p38, ERK1/2 and JNK total protein levels remained unchanged after 
both the doses. However, a dose dependent increase in phosphorylation (activation) of 
all these kinases including AKT, p38, ERK1/2 and JNK was observed after APAP 
treatment (Fig. 2.4.6 B, C, E-H). Activation of all these kinases was higher in APAP600 
group as compared to APAP300 group. Further, similar trend was observed for 
expression of downstream transcription factors c-Jun and c-Fos (Fig. 2.4.6D). Overall, 
these results suggest that signaling through growth factor and downstream MAPKs 
remain activated even at the dose of APAP where liver regeneration is inhibited. Thus, 
lack of activation of these signaling may not be the reason for failed liver regeneration at 
higher dose.  
It should be noted that apart from involvement in cell proliferation and liver 
regeneration pathways (Schwabe, Bradham et al. 2003), JNK activation is also 
considered as one of the important steps in mediating APAP overdose induced liver 
injury (Jaeschke, McGill et al. 2012). Phosphorylation of JNK and its translocation to 
mitochondria early in APAP toxicity leads to exacerbation of mitochondrial oxidant 
stress (Jaeschke, McGill et al. 2012).  Despite previous attempts, the role of JNK 
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activation in liver regeneration after APAP overdose remains undefined and should be 
further evaluated (Bourdi, Korrapati et al. 2008). 
Differential activation of cytokine pathways (IL-6/STAT-3 and TNF-α/NF-κB) during 
liver regeneration after APAP overdose 
Activation of cytokine pathways (IL-6/STAT-3 and TNF-α/NF-κB) is considered 
as important “priming event” that contribute to initiation of early stages of liver 
regeneration after PH (Fausto 2000). However, their role in liver regeneration after 
APAP overdose is not known. IL-6 mRNA was induced at both the doses of APAP as 
early as 3 hr after APAP treatment and remains induced up to 24 hr showing peak at 12 
hr after APAP treatment (Fig 2.4.7A). Interestingly, IL-6 induction was greater at higher 
dose of APAP where regeneration was inhibited. IL-6 binding to its receptor at cellular 
membrane leads to phosphorylation and nuclear translocation of STAT-3, which 
ultimately results in transcription of many target genes. Corroborating IL6 data, we 
observed significantly higher phosphorylation of STAT-3 in APAP600 mice, which 
showed less regeneration (Fig 2.4.7B). While, STAT-3 phosphorylation was transient 
(appeared at 6 and 12 hr) in APAP300 group, it started early (at 3 hr) and maintained till 
24 hr in APAP600 group. Whereas total STAT-3 levels were induced after APAP 
treatment in both doses, no significant difference between the groups was observed. 
Overall these data suggest that, similar to growth factor signaling, IL-6 signaling remain 
intact even at non-regenerative dose of APAP thus may not explain failed liver 
regeneration at higher dose. 
 




Figure 2.4.7. Differential activation of cytokine pathways during liver regeneration after 
APAP overdose. (A) IL-6 and (C) TNF-α mRNA expression in liver of mice treated with either 
300 or 600 mg/kg APAP. Western blot analysis of (B) total STAT-3, phospho STAT-3, (D) total, 
nuclear, phosphorylated p65 and IκB using total liver extract (unless specified) of mice treated 
with either 300 or 600 mg/kg APAP. All samples were collected over a time course of 0 to 24 hr 
after APAP treatment (n = 3-5). (E) ChIP analysis showing p65 binding to Cyclin D1 promoter at 
12 hr after either 300 or 600 mg/kg APAP treatment (n=3). * indicate significant difference 
between two doses at p<0.05 
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Next, we determined the status of NF-κB signaling during liver regeneration after 
APAP-induced ALI using our incremental dose model (Fig. 2.4.7C and D).  TNF-α 
binding to its receptor ultimately results in stabilization and nuclear translocation of 
transcription factor NF-κB (consisting p65 as one of its subunits). Cyclin D1 is a known 
target of NF-κB (Guttridge, Albanese et al. 1999). Interestingly, TNF-α was induced at 
early time points (3 and 6 hr), preceding regenerative phase, specifically in lower 
(regenerative) dose and its mRNA level peaked at 12 hr after APAP treatment. In 
contrast, TNF-α was not induced until 12 hr after APAP in higher dose and overall 
showed much lower induction compared to APAP300 dose (Fig. 2.4.7C).  Further, there 
was marked increase in phosphorylation of p65 at Ser536, a site known to enhance 
transactivation potential of p65(Viatour, Merville et al. 2005), in APAP300 group 
preceding regenerative phase (6 hr after APAP) and sustained until 24 hr (Fig. 2.4.7D). 
Whereas, APAP600 group also showed increase in Ser536 phosphorylation, it was only 
at 12 hr post-APAP and was overall lower than in APAP300 group. While, marked 
nuclear translocation of p65 was observed at both the doses, the increase in nuclear 
p65 was sustained in APAP300 group till 24 hr after APAP but declined sharply at 12 hr 
and 24 hr after APAP in APAP600 group. Total p65 protein expression was increased in 
both the groups at all the time points compared to basal levels and IκB protein level did 
not appear to change at any dose (Fig. 2.4.7D).  
Overall, activation of NF-κB signaling correlated with stimulation of liver 
regeneration at lower dose and we observed indication of inhibited activation of NF-κB 
signaling at higher dose where liver regeneration was inhibited. Considering Cyclin D1 
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is a known target of p-65, we wanted to directly compare p-65 binding to Cyclin D1 
promoter at the two doses using ChIP assay (Fig 2.4.7E). Interestingly, we observed 
around 2.5-fold higher binding of p-65 to Cyclin D1 promoter in APAP300 compared to 
APAP600 group, 12 hr after APAP treatment, which is the time point of peak induction 
of Cyclin D1. All these data suggest that inhibited activation of NF-κB signaling may be 
one of reason for inhibited cyclin D1 induction and inhibited liver regeneration at higher 
dose.  
Activation of Wnt/β-catenin signaling is inhibited following higher dose of APAP 
Previous report have demonstrated involvement of β-catenin activation in liver 
regeneration after PH and APAP induced ALI (Nejak-Bowen and Monga 2011), (Apte, 
Singh et al. 2009). Here, we further analyzed the role of Wnt/ β-catenin signaling in 
detail using our incremental dose model. Whereas total β-catenin protein remained 
unchanged in both the groups at all time points, a substantial increase in nuclear β-
catenin was observed at 12 hr and 24 hr after APAP overdose in APAP300 group (Fig. 
2.4.8A). In contrast, APAP600 exhibited initial increase in nuclear β-catenin at 0.5 and 1 
hr after APAP treatment, which decreased at later time points. The decline in nuclear β-
catenin was consistent with substantial increase in two inactive forms of β-catenin 
(Ser45/Thr41-phosphorylated and Ser33/37/Thr41-phosphorylated) in APAP600 mice. 
To further study the upstream mechanism, we determined expression of total and 
phosphorylated (inactive) form of glycogen synthase kinase-3β (GSK3β), which 
regulates β-catenin degradation in canonical Wnt signaling (Fig. 2.4.8B). Data indicate 
significant inactivation of GSK3β as shown by marked increase in phospho-GSK3β  
 




Figure 2.4.8. Activation of Wnt/β-catenin signaling is inhibited following higher dose of 
APAP. Western blot analysis of (A) total β-catenin, nuclear β-catenin, phospho-β-catenin 
(S45/Thr41), phospho-β-catenin (S33/37/Thr41), (B) total GSK-3β and phospho-GSK-3β. Total 
liver extract (unless specified) of mice treated with either 300 or 600 mg/kg APAP were used for 
Western blots. mRNA expression of (C) Wnt4 and (D) Wnt5a in liver of mice treated with either 
300 or 600 mg/kg APAP. All samples were collected over a time course of 0 to 24 hr after APAP 
treatment (n = 3-5). (E)  ChIP analysis showing β-catenin binding to Cyclin D1 promoter at 12 hr 
after either 300 or 600 mg/kg APAP treatment (n = 3). * indicate significant difference between 
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protein in APAP300 mice between 6 hr to 24 hr after APAP overdose, correlating with β-
catenin activation. Interestingly, higher dose showed initial GSK3β inactivation to some 
extent (less compared to APAP 300), but this inactivation markedly decreased during 
later phase. The decreased inactivation (or increased activation) of GSK3β at 6 to 24 hr 
after APAP treatment in APAP600 group are consistent with increase in phosphorylated 
β-catenin species (inactive). Next we determined protein expression of Dvl, which acts 
upstream of GSK3β in canonical Wnt signaling and is activated by Wnt binding to 
Frizzled (Fzd) receptor. A significant increase in Dvl expression was observed in 
APAP300 group at 12 and 24 hr post-APAP. In contrast, Dvl expression increased early 
after APAP600 dose but declined during the regenerative phase (Fig. 2.4.9).  
To determine if expression of any of the Wnts and Fzds is induced during APAP-
induced liver regeneration, we quantified mRNA of all 11 Wnts and 10 Fzld genes 
known to be expressed in the liver (Zeng, Awan et al. 2007). The data indicate that 
Wnt4 and Wnt5a mRNA exhibited significant induction in APAP300 group during 
regenerative phase (12 and 24 hr) (Fig. 2.4.8C and D). However, none of the Wnt 
mRNAs were induced at any time point following APAP600 dose.  Among the Fzd 
genes, Fzd7 was significantly induced only in APAP300 group between 3 to 12 hr, while 
Fzd8 showed opposite trend with slight but significant induction in APAP600 group at 12 
and 24 hr (Fig. 2.4.9). All other Fzd genes remained unaffected in both groups. 
Overall, we observed stimulation of Wnt/β-catenin signaling specifically in 
regenerating dose correlating with induction of Cyclin D1 which is a known target of β-
catenin (Torre, Benhamouche et al. 2011). Further, activation of Wnt/β-catenin signaling  
 





Figure 2.4.9. (A) Western blot and (B) densitometric analysis of Dvl using total liver extracts 
from mice treated with 300 mg/kg or 600 mg/kg APAP. Real time PCR analysis of (C) Fzd7 and 
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was inhibited at higher dose correlating with inhibited Cyclin D1 induction. Finally, we 
directly checked if there is difference in β-catenin binding to Cyclin D1 promoter at the 
two doses using ChIP assay.  We observed around 2-fold higher enrichment of β-
catenin binding to Cyclin D1 promoter in APAP300 compared to APAP600 group, 12 hr 
after APAP treatment, which is the time point of peak induction of Cyclin D1 (Fig. 
2.4.8E). Taken together, these data suggest that inhibited activation of Wnt/β-catenin 
signaling may be one of reason for inhibited cyclin D1 induction and inhibited liver 
regeneration at higher dose. 
Increased liver regeneration in mice over expressing stable form (S45D) of β-
catenin after APAP overdose 
  Our studies using the incremental dose model identified Wnt/β-catenin signaling 
as potential targets for stimulating liver regeneration after APAP overdose. We further 
confirmed the role of β-catenin in stimulation of liver regeneration after APAP overdose 
using mice over expressing a stable (S45D) form of β-catenin. Preliminary analysis 
showed moderately higher total β-catenin in the S45D mice (Fig. 2.4.10A). Further 
analysis indicated no significant difference in hepatic CYP2E1, the main enzyme 
involved in APAP bioactivation, in S45D mice as compared to WT mice (Fig. 2.4.10A).  
Preliminary studies indicated that the WT controls mice for the S45D strain, which are 
the S45D negative littermates, are more susceptible to APAP than C57BL/6 mice and 
exhibited slightly different time course of liver injury development. Therefore, we initially 
used a dose of 300 mg/kg APAP in this study, which was sufficient to show attenuated 
liver regeneration response in WT mice. WT and S45D mice were treated with 300  
 




Figure 2.4.10. (A) Western blot analysis of total β-catenin and CYP2E1 in WT and S45D mice 
before APAP treatment (n=3-4). Changes in (B) Cyclin D1 and (C) Axin2 mRNA at 24 hr after 
treatment with 300 mg/kg APAP in WT and S45D mice (n=5).  
  
 





Figure 2.4.11. Over expression of stable form of β-catenin improves liver regeneration 
after 300 mg/kg APAP. (A) Representative photomicrographs of H&E stained (upper panel) 
and PCNA-stained (lower panel) liver sections from WT and S45D mice treated with 300 mg/kg 
APAP. Bar graphs showing (B) Serum ALT levels, (C) percent necrosis area and (D) PCNA 
counts in WT and S45D mice treated with 300 mg/kg APAP. (E) Western blot analysis of active 
β-catenin, cyclin D1, pRb and PCNA using total liver extracts in WT and S45D mice treated with 
300 mg/kg APAP (n=5). * indicate significant difference between WT and S45D group at p<0.05. 
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mg/kg APAP and liver injury and regeneration were analyzed at 6 and 24 hr after APAP 
treatment. Serum ALT levels and necrosis scoring demonstrated similar liver injury in 
WT and S45D mice at both the time points after APAP (Fig. 2.4.11A-C) suggesting 
injury process is not altered in S45D mice. While, WT mice showed only a few PCNA 
positive hepatocytes at 24 hr after APAP treatment, liver regeneration was remarkably 
improved in S45D mice as indicated by higher PCNA positive hepatocytes in S45D mice 
at 24 hr after APAP treatment compared to WT mice (Fig. 2.4.11D). This was further 
substantiated by PCNA protein expression, which displayed similar pattern (Fig. 
2.4.11E). Western bot analysis indicated significantly higher activated β-catenin in S45D 
mice at 24 hr after APAP treatment (Fig. 2.4.11E). Increase in activated β-catenin was 
accompanied by increased cyclin D1 and phosphorylation of Rb protein in S45D mice at 
24 hr after APAP overdose (Fig. 2.4.11E). Real Time PCR analysis indicated increase 
gene expression of Cyclin D1 and Axin 2, the known targets of β-catenin, in S45D mice 
following APAP treatment as compared to WT mice at 24 hr after APAP overdose (Fig. 
2.4.10B and C). Next, we studied liver regeneration in S45D mice after higher dose of 
APAP (600 mg/kg) (Fig. 2.4.12A, D and E). Both WT and S45D mice did not show any 
significant liver regeneration at 24 hr after APAP. However, S45D mice showed higher 
PCNA protein expression (with higher PCNA positive cells) compared to WT mice (Fig. 
2.4.12A and D) at 48 hr after APAP treatment. This was further substantiated by higher 
cyclin D1 protein expression and downstream phosphorylation of Rb protein in S45D 
mice compared to WT mice at 48 hr after APAP treatment (Fig. 2.4.12E). Similar to 
APAP300 dose, both WT and S45D mice showed similar injury at 24 and 48 hr after 
APAP600 treatment (Fig. 2.4.12A- C). These data show that overexpression of β- 
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Figure 2.4.12. Over expression of stable form of β-catenin improves liver regeneration 
after 600 mg/kg APAP. (A) Representative photomicrographs of H&E stained (upper panel) 
and PCNA-stained (lower panel) liver sections from WT and S45D mice treated with 600 mg/kg 
APAP. Bar graphs showing (B) Serum ALT levels, (C) percent necrosis area and (D) PCNA 
counts in WT and S45D mice treated with 600 mg/kg APAP. (E) Western blot analysis of active 
β-catenin, cyclin D1, pRb and PCNA using total liver extracts in WT and S45D mice treated with 
600 mg/kg APAP (n=5). * indicate significant difference between WT and S45D group at p<0.05. 
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catenin resulted in faster and higher liver regeneration after APAP overdose. 
2.5 DISCUSSION 
APAP overdose is the foremost cause of ALF in the US contributing to around 
46% of all ALF cases (Lee, Squires et al. 2008). Treatment options after APAP-induced 
ALF are extremely limited. Extensive research on chemicals and drugs that induce liver 
injury has shown that compensatory liver regeneration plays a critical role in 
determination of final outcome of injury. It is known that timely stimulation of 
regeneration leads to regression of injury while failing to regenerate culminates in 
progression of injury and death (Mangipudy, Chanda et al. 1995, Anand, Soni et al. 
2003, Mehendale 2005). Several recent clinical and animal studies showing similar 
findings after APAP overdose suggest that stimulating liver regeneration can be a 
potential treatment option for APAP-induced ALF (Hu and Colletti 2008, Apte, Singh et 
al. 2009, Donahower, McCullough et al. 2010). However, our knowledge regarding 
mechanisms of liver regeneration after APAP-induced injury is extremely limited and 
there is a critical need to study these mechanisms systematically.  
Dynamics of liver regeneration after toxic insult has been extensively studied for 
many toxicants such as thioacetamide (Mangipudy, Chanda et al. 1995), carbon 
tertrachloride (Rao, Mangipudy et al. 1997), and chloroform (Anand, Soni et al. 2003). 
These studies demonstrated that liver regeneration follows classic rules of dose-
response such that regeneration increases with dose of toxicant proportionate to injury. 
This occurs until a threshold dose beyond which the ability of liver to regenerate 
declines leading to progression of injury (Mehendale 2005). Based on this principle, we 
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developed an incremental dose model to study mechanisms of liver regeneration after 
APAP-induced ALI. In this study, we used two doses of APAP, a lower dose (300 
mg/kg) that caused extensive liver injury but also significant compensatory regeneration 
leading to regression of injury and spontaneous recovery and a higher dose (600 
mg/kg) that caused sustained injury, compromised recovery and decreased survival. 
We observed marked inhibition of liver regeneration at higher dose highlighting 
importance of liver regeneration in overall survival after APAP overdose supporting 
previous findings (Hu and Colletti 2008, Apte, Singh et al. 2009, Donahower, 
McCullough et al. 2010). It should be noted that the marked inhibition of regeneration 
was not due to lack of viable hepatocytes at the higher dose. Necrosis score analysis 
and immunohistochemical staining for HNF4α, which stains for viable hepatocytes, 
demonstrated that more than 50% hepatocytes were viable in APAP600 dose at peak 
injury. In fact, overall cellular death was not strikingly different at the two doses at early 
time points where regeneration was initiated at lower dose and inhibited at higher dose. 
These data and further analysis of cell cycle phases indicated that the inhibition of 
regeneration was not simply because of too much cell death but due to inhibited cell 
cycle entry and cell cycle arrest at very early stage in viable cells surrounding necrotic 
zone at higher dose. Higher cellular stress in viable hepatocytes may be a possible 
explanation for this inhibited liver regeneration at higher dose. This observation also 
distinguishes the APAP incremental dose model from 90% partial hepatectomy model, 
where the primary reason behind decreased liver regeneration is lack of critical mass 
required to initiate regeneration.  
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Our most remarkable finding was that Cyclin D1 mRNA and protein expression 
increased in the lower dose preceding the start of regenerative phase but this was 
completely inhibited in the higher dose. These data further support that initial entry into 
cell cycle is inhibited at higher dose underscoring the importance of induction of Cyclin 
D1 in regulation of liver regeneration following APAP-induced ALI. Further, we found 
higher and sustained induction of p21 protein at higher dose supporting possible 
contribution of active inhibition of cell cycle in cell cycle arrest at higher dose due to 
elevated cellular stress. Similar results are reported previously after ethanol treatment in 
PH model, where ethanol inhibited Cyclin D1, induced p21 and impaired liver 
regeneration (Koteish, Yang et al. 2002). Interestingly, there was moderate induction of 
p21 even at regenerative dose suggesting possible role of p21 in coordinating liver 
regeneration. Recent study demonstrating role reversal of p21 in liver regeneration 
depending upon degree of injury certainly supports this possibility (Buitrago-Molina, 
Marhenke et al. 2013). Further studies are required to determine the exact role of p21 in 
liver regeneration after APAP overdose. 
Several regenerative pathways such as growth factors/MAPKs, TNFα/NF-κB, 
Wnt/β-catenin and IL6/STAT-3, are known to induce Cyclin D1 and hepatocyte 
proliferation (Michalopoulos 2007). We determined status of some these pathways in 
our model to look further into mechanism behind differential expression of CyclinD1 at 
both the doses. There was remarkable activation of growth factor receptors (c-Met and 
EGFR), downstream MAPKs (ERK1/2, p38 and JNK) and IL-6/STAT-3 signaling at 
regenerative dose but, interestingly, activation was much higher and sustained at non-
regenerative dose. Previous studies suggest that some of these pathways may be 
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important for normal liver regeneration after APAP overdose where animals 
spontaneously regenerate. For instance, liver regeneration was found to be impaired in 
IL-6 knock out mice after moderate APAP overdose.(James, Lamps et al. 2003) Further 
confirmatory studies are required to demonstrate role of some of these pathways in liver 
regeneration after APAP overdose. However, our data clearly indicate, for the first time, 
that inability to activate these signaling pathways is not limiting regeneration at higher 
dose where animals are not able to recover spontaneously, as these pathways are 
already highly activated at this dose. Additional stimulation of these pathways may not 
be a good strategy from therapeutic standpoint. This also questions administration of 
growth factors as a therapeutic strategy after APAP-induced ALF. This observation is 
consistent with previous reports that administration of growth factors did not affect liver 
regeneration in dogs after APAP-induced ALF (Francavilla, Azzarone et al. 1993). Also 
patients who died after APAP-induced ALF were found to have higher amount of HGF 
circulating in plasma (Hughes, Zhang et al. 1994).  
These data give rise to two possibilities. First, an active inhibitory signaling is 
blocking liver regeneration at higher dose counteracting these regenerative signaling. 
Activation of cell cycle inhibitors (e.g. p21) is one such signaling pathway that we 
observed in this study.  Moreover, some of the known regenerative pathways, which are 
highly activated in APAP600, may be actively involved in inhibiting regeneration. For 
instance, over-activation of p38 has been associated with decreased regeneration in PH 
model (Koteish, Yang et al. 2002, Horimoto, Fulop et al. 2004). Also, p38 can directly 
inhibit Cyclin D1 expression (Lavoie, L'Allemain et al. 1996). Similarly impaired 
regeneration after PH in ob/ob mice with fatty liver or in mice with hyper-stimulated IL6 
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signaling was correlated with sustained and over-activation of STAT3 (Wustefeld, 
Rakemann et al. 2000, Torbenson, Yang et al. 2002). Further, sustained activation of 
these mediators was correlated with induction of p21 and inhibition of Cyclin D1, which 
is consistent with our data.  
 The second possibility is that specific critical pathways apart from the growth 
factor-mediated pro-regenerative signaling regulate liver regeneration after APAP 
overdose. Previous studies have shown that Wnt/β-catenin pathway plays a critical role 
in liver regeneration in general and after APAP over dose in particular (Apte, Singh et al. 
2009, Nejak-Bowen and Monga 2011).  Consistent with these data, we observed 
activation of canonical Wnt signaling at regenerative dose. More interestingly, β-catenin 
activation was inhibited at higher dose where liver regeneration was inhibited. We also 
observed TNF-α/NF-κB signaling activation at regenerative dose supporting previous 
studies showing role of TNF receptor in liver regeneration after APAP overdose(Chiu, 
Gardner et al. 2003, James, Kurten et al. 2005).  Further, previous data showed 
increased NF-κB DNA binding after APAP treatment, which was correlated positively 
with regeneration in mice (Yang, Miki et al. 2009, Yang, Zhang et al. 2011). 
Interestingly, similar to β-catenin signaling, our results indicated that activation of TNF-
α/NF-κB signaling is inhibited at higher dose where recovery is compromised. Both, β-
catenin and NF-κB are known to transcriptionally regulate and induce Cyclin D1 directly 
(Guttridge, Albanese et al. 1999, Torre, Benhamouche et al. 2011). Our ChIP data 
support important role of such regulation in liver regeneration after APAP overdose. Our 
findings implicate that inhibited activation of Wnt/β-catenin and TNF-α/NF-κB signaling 
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may be contributing factor to inhibited liver regeneration after severe APAP overdose 
and thus could be potential target for stimulating liver regeneration therapeutically. Over 
activation of beta-catenin is known to accelerate liver regeneration after PH (Nejak-
Bowen, Thompson et al. 2010, Nejak-Bowen and Monga 2011). Further, our previous 
study showed correlation of beta-catenin activation with higher spontaneous liver 
regeneration and survival in APAP-induced ALF patients (Apte, Singh et al. 2009). In 
the current study, we observed that mice overexpressing mutated form of β-catenin 
have better liver regeneration after low and high dose of APAP. Our data for the first 
time indicated that stimulating canonical Wnt signaling could be a viable approach for 
improving liver regeneration in APAP-induced ALF patients. 
In summary, our findings using a novel comparative model have demonstrated 
that high doses of APAP will inhibit liver regeneration due to active inhibition of cell 
cycle progression and/or by lack of stimulation via critical pro-mitogenic pathways. 
Some interesting potential pathways that may be involved in active inhibition of liver 
regeneration include p38 MAPK and IL-6 signaling and require further detailed 
investigation. Further, this study has revealed canonical Wnt signaling and NF-κB 
signaling as potential therapeutic targets to stimulate liver regeneration after APAP 
overdose. Finally, our studies indicate that concomitant inhibition of several inhibitory 
pathways and activation of various stimulatory pathways may have promising future in 


















CHAPTER III: INHIBITION OF GSK3 ACCELERATED LIVER REGENERATION 




















Overdose of acetaminophen (APAP) is the leading cause of acute liver failure (ALF) in 
the US with very limited treatment options. Timely initiation of compensatory liver 
regeneration after APAP-induced hepatotoxicity is critical for final recovery and survival. 
Stimulating liver regeneration in patients of APAP-induced ALF holds a great 
therapeutic potential, but development of novel regenerative therapies for ALF is 
hampered because the mechanisms of liver regeneration after APAP-induced ALF have 
not extensively explored yet. Here we investigated the role of glycogen synthase 
kinase-3 (GSK3) in liver regeneration after APAP-induce hepatotoxicity, which is 
currently unknown. GSK3 was rapidly inactivated after moderate APAP overdose (300 
mg/kg) in mice, which corresponded to timely stimulation of compensatory liver 
regeneration. GSK3 inactivation was remarkably reduced after higher dose of APAP 
(600 mg/kg), where liver regeneration was attenuated and delayed. Treatment with 
selective GSK3 inhibitor (L803-mts), starting from 4 hr after 600 mg/kg dose of APAP, 
resulted in early initiation of liver regeneration without any alteration of APAP-induced 
hepatotoxicity in mice. Interestingly, early liver regeneration after GSK3 inhibition was 
associated with improved survival. Early cell cycle initiation in hepatocytes after GSK3 
inhibition was due to rapid induction of cyclin D1 and phosphorylation of retinoblastoma 
protein. This was associated with increased activation of β-catenin signaling after GSK3 
inhibition. Taken together, our study has revealed a novel role of GSK3 in liver 
regeneration after APAP overdose and identified GSK3 as a potential therapeutic target 
to improve liver regeneration after APAP-induced ALF.   
 
 




Liver injury caused by acetaminophen (APAP) overdose is the leading cause of acute 
liver failure (ALF) in the western world, accounting nearly half of all the ALF cases (Lee, 
Squires et al. 2008, Lee 2012). Despite decades of research, current treatment options 
after APAP-overdose are extremely limited.  N-acetylcysteine (NAC) is the current 
standard of care for APAP overdose patients, which is effective only at an early stage 
(Athuraliya and Jones 2009, Bernal, Lee et al. 2015). Mechanisms of liver injury after 
APAP overdose have been extensively investigated in past in order to develop novel 
therapeutic strategies. However, many patients seek medical attention late after liver 
injury is already established and difficult to manipulate (Larson 2007). Liver injury after 
APAP-overdose is subsequently followed by compensatory liver regeneration, which is 
critical for recovery. Previous studies from our laboratory and others have demonstrated 
that liver regeneration is a critical determinant of survival after APAP overdose (Schmidt 
and Dalhoff 2005, Hu and Colletti 2008, Apte, Singh et al. 2009, Donahower, 
McCullough et al. 2010). Liver regeneration is a parameter that can be potentially 
modulated even at a late stage in pathogenesis of APAP-induced ALF and stimulating 
liver regeneration in patients of APAP-induced ALF holds a great therapeutic potential. 
However, development of novel regenerative therapies for ALF is hampered because 
the mechanisms of liver regeneration after APAP-induced ALF have not extensively 
explored yet. Mechanisms of liver regeneration are mostly studied in partial 
hepatectomy (PH) model (Michalopoulos 2007), which is considerably different from 
APAP-hepatotoxicity, the model of clinical ALF (Bhushan, Walesky et al. 2014).   
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Glycogen synthase kinase-3 (GSK3) is a ubiquitously expressed serine/threonine 
protein kinase, which is constitutively active in cells under resting state and primarily 
regulated by inactivation (Kaidanovich-Beilin and Woodgett 2011). GSK3 is downstream 
of a number of major signaling pathways including growth factors, insulin and canonical 
Wnt signaling, which negatively regulate GSK3 activity. GSK3 activity is primarily 
regulated by phosphorylation-mediated inactivation, but other methods of inactivation 
such as sequestration and subcellular localization are also known (Jope and Johnson 
2004). Initially discovered to regulate glycogen synthase, GSK3 is now known to 
regulate a wide spectrum of proteins and affect a number of cellular functionalities 
including proliferation, differentiation and survival (Jope and Johnson 2004). GSK3 
functions by phosphorylation-mediated inactivation/ degradation of its substrates. As a 
subunit of β-catenin destruction complex, GSK3 causes phosphorylation mediated 
targeting of β-catenin for proteosomal degradation, thus negatively regulating β-catenin 
signaling (Doble and Woodgett 2003).  Apart from β-catenin, GSK3 can regulate many 
other cell proliferation mediators such as Cyclin D1, c-Myc, c-Jun, and eIF2B 
(Sutherland 2011).  
Inhibitors of GSK3 have been reported to induce in-vitro expansion of mouse primary 
hepatocytes (Ito, Kamiya et al. 2012) and facilitate survival signaling via activation of β-
catenin in them (Gotschel, Kern et al. 2008). Further, GSK3 negatively regulates β-
catenin, which plays a critical role in liver regeneration (Tan, Behari et al. 2006, Sekine, 
Gutierrez et al. 2007, Nejak-Bowen, Thompson et al. 2010, Nejak-Bowen and Monga 
2011). Interestingly, other studies indicate that GSK3 may play a pro-regenerative role 
after PH (Chen, Yang et al. 2007, Jin, Wang et al. 2009, Sekiya and Suzuki 2011). 
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Treatment with GSK3 inhibitor or siRNA mediated downregulation of GSK3 has 
reported to impair liver regeneration in mice and rats after PH (Chen, Yang et al. 2007, 
Jin, Wang et al. 2009, Sekiya and Suzuki 2011). Antisense oligonucleotides mediated 
silencing of GSK3β has reported to inhibit APAP-induced injury, attributed to role of 
GSK3β in initiation of APAP toxicity (Shinohara, Ybanez et al. 2010). However, role of 
GSK3 in compensatory liver regeneration after APAP-induced liver injury is not known. 
In previous chapter, we established an incremental dose model in mice to study 
mechanisms of liver regeneration after APAP-induced ALF, which has revealed a 
number of signaling pathways involved in liver regeneration after APAP overdose. 
These data also showed that inactivation of GSK3β is positively correlated with early 
initiation of liver regeneration after APAP overdose. Further, overexpression of β-
catenin resulted in improved liver regeneration after APAP-induced liver injury. Here, we 
investigated direct role of GSK3 in compensatory liver regeneration after APAP 
overdose using pharmacological inhibitor of GSK3. Based on our previous findings, we 
hypothesized that inhibition of GSK3 after APAP treatment will result in enhanced liver 
regeneration. Here we report that treatment with L803-mts, a selective GSK3 inhibitor, 
accelerate liver regeneration after APAP overdose via early activation of β-catenin and 
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3.3 MATERIALS AND METHODS 
Animals, treatments and tissue harvesting  
Eight weeks old, C57BL/6J mice were purchased from Jackson Laboratories and used 
in all the studies. All animals were housed in Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC)-accredited facilities at the University 
of Kansas Medical Center under a standard 12-hr light/dark cycle with access to chow 
and water ad libitum. All studies were approved by The Institutional Animal Care and 
Use Committee at the University of Kansas Medical Center. APAP (Sigma, St. Louis, 
MO) was dissolved in warm 0.9% saline and administered intraperitoneally (i.p.). Mice 
were fasted overnight before APAP administration. For study with incremental doses of 
APAP, mice (n = 3 to 7) were treated with either 300 or 600 mg/kg APAP, and sacrificed 
at 0, 3, 6, 12, 24, 48, 72 and 96 hr following APAP treatment. For GSK3 inhibition 
studies, a substrate competitive peptide inhibitor of GSK3, L803-mts: N-myristol-
GKEAPPAPPQS(p)P (Genemed Synthesis, San Francisco, CA) was used. GSK3 
inhibitor (GSK3i) was dissolved in warm phosphate-buffered saline (PBS) and 
administered 4 hr after APAP (600 mg/kg) treatment, followed by treatments every 24 hr 
until sample collection. For preliminary study, GSK3i was administered at doses of 400 
and 800 nmol per mouse and animals (n = 3-4) were euthanized 24 hr after APAP 
treatment. In the following studies, 800 nmol/mouse dose of GSK3i was administered 
and mice (n=4-12) were sacrificed at 18, 24, 48 and 72 hr after treatment with APAP. 
Euthanasia was performed by cervical dislocation under isoflurane anesthesia, and 
blood and livers were collected. Serum samples were obtained from the blood and used 
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for further analysis. Liver sections were prepared for histological analysis as described 
previously (Wolfe, Thomas et al. 2011).   
Histological analysis and serum ALT measurement 
Paraffin-embedded liver sections (4 µm thick) were used for H&E staining and scored 
for percentage necrotic area. Serum alanine aminotransferase (ALT) was measured 
using the Infinity ALT kit (ThermoFisher Scientific, Pittsburgh, PA), according to the 
manufacturer’s protocol. 
Immunohistochemistry 
Paraffin-embedded liver sections (4 µm thick) were used for immunohistochemical 
detection.  PCNA staining was performed for cell proliferation analysis as described 
before (Wolfe, Thomas et al. 2011). Anti-PCNA antibody was purchased from Cell 
Signaling Technologies (Danvers, MA). Biotinylated secondary antibody was purchased 
from Jackson Immunoresearch (West Grove, PA).  
Protein isolation and western blot analysis 
Total cell lysate was prepared from frozen liver tissues as described previously 
(Bhushan, Borude et al. 2013). Protein estimation and western blot analysis was 
performed using individual or pooled samples of protein extracts as previously 
described in detail (Wolfe, Thomas et al. 2011). All primary and secondary antibodies 
were obtained from Cell Signaling Technologies (Danvers, MA), unless stated 
otherwise. Active β-catenin antibody was purchased from EMD Millipore (Billerica, MA). 
Image J software was used for densitometric analysis of western blot images.  
 




Data presented in the form of bar/line graphs show mean ± SEM. Significant difference 
between two groups was determined using Student’s t-test and between three or more 
groups using one-way analysis of variance (ANOVA) with Tukey's post-hoc test. 








Rapid inactivation of GSK3β associated with early and robust liver regeneration 
at lower dose of APAP, which was attenuated at higher dose   
Our work in previous chapter established an incremental dose model to study 
mechanisms of liver regeneration after APAP-induced ALF. Two doses of APAP (300 
mg/kg and 600 mg/kg) were administered in separate groups of mice. Lower dose 
caused extensive liver injury, but injury was followed by robust compensatory liver 
regeneration leading to recovery. In contrast, at higher dose, liver regeneration was 
lower and delayed leading to decreased survival. Interestingly, inactivation of GSK3β 
was higher in regenerating dose treated mice and positively correlated with 
compensatory liver regeneration after APAP overdose. In the current study, inactivation 
of GSK3β was examined after incremental doses of APAP (300 mg/kg and 600 mg/kg) 
in mice over an extended time-course up to 96 hr (Fig. 3.4.1A and B). Interestingly, 
rapid increase in phosphorylation at Ser 9 residue of GSK3β (which is known to cause 
inactivation of GSK3β) was observed at the earliest investigated time point of 3 hr and 
peaked at around 6 to 12 hr after treatment with lower dose of APAP. Phosphorylation 
of GSK3β was gradually decreased at later time and reached around basal levels at 96 
hr. Some phosphorylation of GSK3β was also observed at 3 to 12 after higher dose of 
APAP, but remarkably lesser compared to lower dose after 3 hr. In fact, phosphorylation 
of GSK3β rapidly decreased to basal levels at 24 hr and remained at similar low levels 
at later time points up to 96 hr after higher dose of APAP (Fig. 3.4.1A and B). As 
reported in previous chapter, increase in expression of proliferating cell nuclear antigen  
 




Figure 3.4.1. Rapid inactivation of GSK3β associated with early and robust liver 
regeneration at lower dose of APAP, which was attenuated at higher dose. (A) Western 
blot analysis of phospho-GSK3β (Ser9),  GSK3β, Cyclin D1 and PCNA in total cell lysate of liver 
at various time points after administration of 300 mg/kg and 600 mg/kg APAP in mice (n=3-5). 
Densitometric analysis showing (B) GSK3β inactivation, (C) Cyclin D1 and (D) PCNA protein 
expression based on western blot images shown in (A).  
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(PCNA), which is a maker of cell proliferation, was remarkably lower and delayed at 
higher dose compared to lower dose (Fig. 3.4.1A and D). Similar pattern was observed 
for protein expression of core cell cycle protein, Cyclin D1, which governs entry into cell 
cycle (Fig. 3.4.1A and C). Thus, inactivation of GSK3β was found to be positively 
correlated with early initiation of liver regeneration after APAP overdose.   
Pharmacological inhibition of GSK3 caused dose-dependent improvement in 
proliferation parameters without altering APAP hepatotoxicity  
In the initial dose finding study, L803-mts, a highly selective GSK3 inhibitor (GSK3i), 
was administered 4 hr after treatment with high dose of APAP (600 mg/kg) in mice.  
L803-mts (N-myristol-GKEAPPAPPQS(p)P) is a substrate-competitive fatty acid-
conjugated peptide inhibitor of GSK3. It contains a phosphorylated site that specifically 
mimics primed GSK3 substrate providing it selectivity. Selectivity is the major issue for 
protein kinase inhibitors which are mostly ATP-competitive (Plotkin, Kaidanovich et al. 
2003). Further, fatty acid moiety of the inhibitor provides cell permeability and stability in 
vivo (Plotkin, Kaidanovich et al. 2003). All analysis was performed 24 hr after APAP 
treatment. Two doses of GSK3i (400 nmol and 800 nmol) were used based on previous 
in vivo studies in mice (Plotkin, Kaidanovich et al. 2003, Rao, Hao et al. 2007). APAP 
treatment caused significant liver necrosis in the centrilobular region and elevation of 
serum ALT levels (Fig 3.4.2A and B). APAP-mediated liver injury was not altered by 
treatment with any of the two doses of GSK3i as indicated by histopathological analysis 
of liver sections (Fig 3.4.2A) and serum ALT levels (Fig 3.4.2B). Next, Cyclin D1 and  
 




Figure 3.4.2. Pharmacological inhibition of GSK3 resulted in dose dependent 
improvement in liver regeneration parameters without alteration of APAP-induced 
hepatotoxicity. (A) Representative photomicrographs of H&E stained liver sections with 
necrotic area outlined; (B) Serum ALT levels; (C) Western blot analysis of Cyclin D1 and PCNA 
in liver lysate with their densitometric analysis shown in (D) and (E), respectively.  All samples 
were collected at 24 hr after treatment with 600 mg/kg APAP. Vehicle (PBS) and L803 mts (400 
and 800 nmol/mouse) were administered 4 hr after treatment with APAP (n=3-4). * indicate 
significant difference with respect to vehicle treated group at p<0.05.  
 
 
   
  
72
PCNA protein expression levels were studied as a measure of liver regeneration using 
western blot analysis. Despite similar injury, GSK3i treatment caused significant 
increase in both CyclinD1 and PCNA protein expression at 24 hr after APAP treatment 
(Fig 3.4.2C-E).  Further, increase in expression of these proteins was dose-dependently 
higher after treatment with 800 nmol compared to 400 nmol dose of GSK3i. 800 nmol 
dose of GSK3i was selected for following comprehensive time-course analysis of liver 
injury and regeneration.    
Inhibition of GSK3 did not alter APAP-induced hepatotoxicity but improved 
survival 
Next, 800 nmol of GSK3i was administered starting from 4 hr after treatment with 600 
mg/kg APAP in mice. Liver injury was studied over a time-course of 18 to 72 hr to cover 
both peak toxicity and liver regeneration time-points. Liver injury was studied using 
histopathological analysis of H&E stained liver sections and serum ALT levels (Fig 
3.4.3A-C). APAP caused extensive liver necrosis (around 50% percentage necrotic 
area) at 18 hr after APAP treatment (Fig 3.4.3A and B). Liver necrosis was sustained at 
all later time points up to 72 hr as reported in previous chapter for high dose of APAP 
treatment. Treatment with GSK3i did not significantly alter APAP-induced liver necrosis 
at any of the investigated time points (Fig 3.4.3A and B). Further, serum ALT analysis 
corroborated the histopathological results (Fig 3.4.3C). Some decrease in serum ALT 
levels with time was observed in both the groups despite sustained necrotic areas. This 
is expected due to limited half-life of ALT in serum and is consistent with our results in 
previous chapter.  Very interestingly, despite no alteration in development of  
 




Figure 3.4.3. Inhibition of GSK3 did not alter APAP-induced hepatotoxicity but improved 
survival. (A) Representative photomicrographs of H&E stained liver sections with necrotic area 
outlined, (B) percentage necrosis area based on H&E stained liver sections, (C) serum ALT 
levels (n=4-5), and (D) survival analysis of mice treated with 600 mg/kg APAP followed by 
treatment with L803-mts (800 nmol/mouse) or PBS (n=4-12). L803-mts or PBS was 
administered 4 hr post-APAP followed by every 24 hr until sample collection. All samples were 
collected and survival was recorded at 18, 24, 48 and 72 hr after APAP treatment.    
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 APAP-induced liver injury, GSK3i treatment improved survival (Fig. 3.4.3D). No 
mortality was observed in any of the two groups up to 24 hr after APAP treatment. 20% 
and 60% mortality was observed in APAP-alone treatment group at 48 and 72 hr, 
respectively. In contrast, no mortality was observed in GSK3i-treated group at 48 hr and 
only 20% mortality was observed at 72 hr (Fig. 3.4.3D). 
Inhibition of GSK3 caused early hepatocyte proliferation and liver regeneration 
after APAP overdose   
Next, we investigated effect of GSK3 inhibition on compensatory liver regeneration after 
APAP-induced liver injury. Liver regeneration was studied by immunohistochemical 
analysis of PCNA over the time-course of 18 to 72 hr after APAP administration with or 
without treatment of GSK3i (Fig. 3.4.4A and B). Very few PCNA-positive cells were 
observed at 18 and 24 hr after 600 mg/kg APAP treatment consistent with our results in 
previous chapter. Significant number of positive cells was observed only at 48 and 72 hr 
in APAP-alone treated group. Interestingly, GSK3i inhibition caused early entry into cell 
cycle with PCNA positive cells observed surrounding the necrotic zones even at 18 hr. 
Drastic increase in number of PCNA-positive cells was observed at 24 hr in GSK3i-
treated group. However, number of PCNA-positive cells were comparable to APAP-
alone treated group at 48 and 72 hr (Fig. 3.4.4A and B). These data were corroborated 
with protein expression of PCNA as analyzed using western blot (Fig. 3.4.5A and C; Fig. 
3.4.6A-C). Protein expression of PCNA was increased starting from 24 hr in GSK3i-
treated group, while PCNA expression was increased only after 48 hr in APAP-alone 
treated group. Significantly higher number of PCNA-positive cells and higher PCNA  
 




Figure 3.4.4. Inhibition of GSK3 caused early hepatocyte proliferation and liver 
regeneration after APAP overdose. (A) Representative photomicrographs of PCNA stained 
liver sections with arrows indicating cells with nuclear PCNA staining (brown). (B) Total number 
of PCNA-positive cell per high power field (x40). Liver section were obtained from mice (n=4-5) 
treated with 600 mg/kg APAP followed by treatment with L803-mts (800 nmol/mouse) or PBS. 
L803-mts or PBS was administered 4 hr post-APAP followed by every 24 hr until sample 
collection. All samples were collected at 18, 24, 48 and 72 hr after APAP treatment. * indicate 
significant difference between groups at p<0.05.    
 




Figure 3.4.5. GSK3 inhibition caused early expression of CyclinD1 and PCNA after APAP 
overdose. (A) Western blot analysis of Cyclin D1 and PCNA in pooled total cell lysate with their 
densitometry based on analysis of individual samples shown in (B) and (C), respectively.  All 
liver samples were obtained from mice (n=4-5) treated with 600 mg/kg APAP followed by 
treatment with L803-mts (800 nmol/mouse) or PBS. L803-mts or PBS was administered 4 hr 
post-APAP followed by every 24 hr until sample collection. All samples were collected at 18, 24, 
48 and 72 hr after APAP treatment. * indicate significant difference between groups at p<0.05.     
 
 





Figure 3.4.6. Western blot analysis of Cyclin D1 and PCNA in total cell lysate at (A) 24 hr, (B) 
48 hr and (C) 72 hr after APAP treatment. All liver samples were obtained from mice (n=5) 
treated with 600 mg/kg APAP followed by treatment with L803-mts (800 nmol/mouse) or PBS. 
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protein expression was observed at 24 hr after APAP administration in GSK3i-treated 
group. These data demonstrated that inhibition of GSK3i resulted in early liver 
regeneration after APAP-induced liver injury.   
GSK3 inhibition caused early and sustained expression of CyclinD1 after APAP 
overdose  
Next, we sought to investigate mechanism of early increase in liver regeneration after 
GSK3 inhibition. Induction of Cyclin D1 is a critical limiting factor that controls entry into 
cell cycle and commitment to cell cycle progression in hepatocytes (Fausto 2000). 
Cyclin D1 protein expression was 3-fold higher in GSK3i-treated group at 18 hr post-
APAP and 8-fold higher at 24 hr compared to APAP-alone treated group (Fig 3.4.5A 
and B). This correlated with early hepatocytes proliferation after GSK3 inhibition. 
Further, Cyclin D1 expression increased with time in GSK3i-treated group. Increase in 
Cyclin D1 expression was also observed in APAP-alone treated group but at delayed 
time point of 48 and 72 hr.  However, Cyclin D1 expression consistently remained 
remarkably higher in GSK3i-treated group at all the investigated time points compared 
to APAP-alone treated group (Fig 3.4.5A and B; Fig. 3.4.6A-C).     
Inhibition of GSK3 resulted in increased activation of β-catenin after APAP 
overdose 
Finally, we investigated the signaling mechanism(s) involved in early increase in cyclin 
D1 expression and increase in liver regeneration after GSK3 inhibition. GSK3 is known 
to  negatively regulate β-catenin signaling (Kaidanovich-Beilin and Woodgett 2011) and 
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we reported in previous chapter that stimulation of β-catenin signaling can improve liver 
regeneration after APAP-induced liver injury. Therefore, we investigated effect on β-
catenin signaling in our study. We analyzed the earliest time point of 18 hr that 
preceded robust increase in liver regeneration response in GSK3i-treated group. GSK3 
causes phosphorylation of β-catenin at Thr41, Ser33 and Ser37 ultimately leading to 
proteosomal-mediated degradation of β-catenin (Kaidanovich-Beilin and Woodgett 
2011). Phosphorylation of β-catenin was found to be significantly decreased in GSK3i-
treated group, 18 hr after APAP administration, as studied using antibody that 
specifically recognizes Thr41, Ser33 or Ser37 phosphorylation of β-catenin (Fig. 3.4.7A 
and B). This was corroborated with 5-fold increase in active β-catenin levels 
(dephosphorylated form) in GSK3i-treated group (Fig. 3.4.7A and C). Total β-catenin 
levels were not altered by GSK3i treatment (Fig. 3.4.7A). Stable (unphosphorylated) β-
catenin translocates to nucleus and induces its target genes, which includes cell 
proliferation genes such as Cyclin D1. Increase in β-catenin signaling was consistent 
with observed early increase in Cyclin D1 levels at 18 hr after APAP treatment in GSK3i 
group (Fig. 3.4.5A and B, 3.4.7A and D). Cyclin D1 binds with CDK4 and causes its 
activation, which then phosphorylates Rb protein, ultimately leading to induction of 
several key cell cycle genes (Fausto 2000). Further, we observed increased 
phosphorylation of Rb protein in GSK3i group at 18 hr after APAP treatment 
corresponding with increased Cyclin D1 expression (Fig. 3.4.7A and E). Thus our 
results demonstrated that early activation of β-catenin after GSK3i inhibition might be 
involved in early entry into cell cycle and accelerated liver regeneration after APAP-
induced liver injury.  
 




Figure 3.4.7. Inhibition of GSK3 resulted in increased activation of β-catenin after APAP 
overdose. (A) Western blot analysis of active β-catenin, phospho β-catenin 
(Thr41/Ser33/Ser37), total  β-catenin, Cyclin D1 and phospho-Rb in total cell lysate with their 
densitometric analysis shown in (C), (B), (D) and (E), respectively.  All liver samples were 
obtained from mice (n=4) treated with 600 mg/kg APAP followed by treatment with L803-mts 
(800 nmol/mouse) or PBS. L803-mts or PBS was administered 4 hr post-APAP and samples 
were collected at 18 hr after APAP treatment. * indicate significant difference between groups at 
p<0.05.     
 




Although mechanisms of APAP hepatotoxicity have been extensively studied leading to 
considerable progress in our knowledge, mechanisms of compensatory liver 
regeneration that follows liver injury after APAP overdose have just begun to be 
explored, which have great potential to be utilized to find novel therapeutic targets. Here 
we investigated role of GSK3 in liver regeneration after APAP-induce hepatotoxicity, 
which is currently unknown.  
GSK3β was rapidly inactivated preceding robust liver regeneration response after 
moderate APAP overdose. Inactivation of GSK3β was greatly diminished at higher dose 
of APAP, where liver regeneration was remarkably attenuated and delayed. This 
positive correlation of GSK3β inactivation with early liver regeneration suggested a 
possible role of GSK3 inactivation in liver regeneration after APAP-induced 
hepatotoxicity. Consistent with this hypothesis, pharmacological inhibition of GSK3 
using selective inhibitor of GSK3 caused dose-dependent early hepatocyte proliferation 
and liver regeneration after APAP-induced hepatotoxicity. These data suggest that 
GSK3 may inhibit liver regeneration after APAP overdose and an inability to cause 
timely inactivation of GSK3 may be responsible for delayed liver regeneration at higher 
dose of APAP. The pro-proliferative role of GSK3 inhibition is consistent with previous 
report where inhibitor of GSK3 induced in-vitro expansion of hepatocytes (Ito, Kamiya et 
al. 2012). However, our finding is contradictory to few previous reports where inhibition 
or siRNA mediated downregulation of GSK3 resulted in impaired hepatocyte 
proliferation after PH (Chen, Yang et al. 2007, Jin, Wang et al. 2009, Sekiya and Suzuki 
 
   
  
82
2011). These discrepancies in findings may be due to inherent differences in models 
used to study of liver regeneration. APAP overdose has significant mechanistic 
difference from PH including presence of significant cell death, liver injury, oxidative 
stress, and asynchronous nature of cell cycle. Our study highlights the notion that same 
signaling pathway may have different and sometimes opposite role in different models 
of regeneration. These studies also underscore the importance of investigating 
mechanisms of liver regeneration after APAP overdose separately from PH to 
determine the inherent model associated differences.  
We further investigated the potential mechanisms underlying role of GSK3 inactivation 
in causing early initiation of liver regeneration after APAP-induced hepatotoxicity.  
Inhibition of GSK3 caused consistent increase in cyclin D1 expression. Thus, early 
initiation of liver regeneration after GSK inhibition was most possibly due to early 
induction of cyclin D1 (which governs entry into cell cycle) and subsequent 
phosphorylation of Rb protein.  Further, our results demonstrate that early activation of 
β-catenin after GSK3 inhibition might be involved in early induction in cyclin D1 and 
accelerate liver regeneration after APAP-induced liver injury. This corroborated our 
findings in previous chapter that overexpression of stable form of β-catenin signaling in 
mice increased cyclin D1 expression and improved liver regeneration; and β-catenin KO 
mice showed decreased liver regeneration after APAP-induced liver injury (Apte, Singh 
et al. 2009). Similar to our findings in APAP model, overexpression of β-catenin in mice 
resulted in early initiation of liver regeneration in PH model with increased expression of 
cyclin D1 without altering peak liver regeneration (Nejak-Bowen, Thompson et al. 2010). 
Further, liver-specific β-catenin deletion in mice caused delayed liver regeneration after 
 
   
  
83
PH, which was correlated with decreased cyclin D1 induction (Tan, Behari et al. 2006, 
Sekine, Gutierrez et al. 2007). Apart from negative regulation of β-catenin, GSK3 can 
directly regulate several other cell proliferation mediators including cyclin D1, c-Myc, c-
Jun and eIF2B (Kaidanovich-Beilin and Woodgett 2011, Sutherland 2011). Thus, GSK3 
could also potentially alter liver regeneration after APAP overdose in β-catenin-
independent manner, which remained to be investigated. 
Shinohara et al. recently reported an attenuation of APAP hepatotoxicity upon antisense 
oligonucleotides mediated silencing of GSK3β (Shinohara, Ybanez et al. 2010). This 
was attributed to role of GSK3β in liver injury initiation through JNK activation and Mcl-1 
degradation. In our study, treatment with GSK3i did not alter APAP-induced 
hepatotoxicity at any of the investigated time points. Further, we did not observe any 
alteration of APAP-mediated JNK activation by GSKi treatment (data not shown). These 
discrepancies are due to differences in experimental design. In our study, GSK3i was 
administered 4 hr after APAP such that injury initiation events have already taken place, 
while pretreatment strategy was utilized in the previous study. In fact, we purposefully 
used post-treatment strategy such that APAP injury initiation was not interfered. This is 
because, any alteration in injury can have secondary effects of liver regeneration and 
the purpose of the study was to study direct role of GSK3 in liver regeneration. Thus our 
study indicated that effect of accelerated liver regeneration is directly mediated by 
GSK3 inhibition and is not secondary to altered injury.   
Very interestingly, survival was improved after GSK3 inhibition without any alteration of 
injury. It should be noted that all the existing clinically used markers for prediction of 
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outcome in ALF patients are solely based on injury parameters and are far from reliable 
in predicting outcome (Lee 2012).  Thus, it is not surprising that survival was not 
correlated with liver injury in our model. Recent studies have demonstrated critical role 
of timely liver regeneration in determining final outcome after APAP overdose (Hu and 
Colletti 2008, Apte, Singh et al. 2009, Donahower, McCullough et al. 2010). Further, 
markers of liver regeneration such as α-Feto protein were reported to correlate with final 
outcome in APAP-induced ALF patients (Schmidt and Dalhoff 2005). On similar line, in 
our study early liver regeneration response after GSK3 inhibition was associated with 
increased survival. Further, this is corroborated by our previous finding where β-catenin 
activation was correlated with higher spontaneous liver regeneration, avoiding need for 
liver transplantation in ALF patients (Apte, Singh et al. 2009). In spite of these 
correlations, further studies are required to establish causal role of early liver 
regeneration in improved survival observed in our study.    
In the past, the primary focus of research in the area of APAP-inflicted liver 
pathophysiology has been mechanisms of initiation APAP hepatotoxicity and targeting 
liver injury for development of therapeutic strategies. However, many of the APAP 
overdose patients typically seek medical attention late after APAP overdose such that 
injury is already established (Larson 2007). Even after decades of research, NAC is still 
the only standard therapy for APAP overdose which is effective only at very early stage 
(Bernal, Lee et al. 2015). In mice, NAC does not provide protection when administered 
4 hr post-APAP (James, McCullough et al. 2003). Liver regeneration is a parameter that 
can be potentially modulated even at the late stage in the APAP-induced ALF and thus 
is an attractive therapeutic target. In our study, initiating GSK3i treatment 4 hr after 
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APAP overdose in mice showed indication of improved liver regeneration parameters 
and survival. Time window of therapeutic effectiveness of GSK3i is expected to be 
much more in humans considering that the pathogenesis of APAP hepatotoxicity is 
generally delayed in humans compared to mice (Xie, McGill et al. 2014). Our study has 
highlighted the potential therapeutic value of improving liver regeneration even after a 
delayed intervention following APAP overdose. Thus, future investigations on similar 
lines are warranted to identify novel therapeutic targets to stimulate live regeneration 
after APAP-induced hepatotoxicity, which are currently underexplored.     
In conclusion, our study revealed novel inhibitory role of GSK3 in timely liver 
regeneration response after APAP-induced hepatotoxicity. Inhibition of GSK3 
accelerated liver regeneration after APAP overdose associated with early induction of 
Cyclin D1, increased β-catenin signaling and improved survival. Thus, our study 
suggested inhibition of GSK3 as a potential therapeutic strategy to improve liver 
regeneration after APAP-induced ALF.  
 
 

















CHAPTER IV: ROLE OF EPIDERMAL GROWTH FACTOR RECEPTOR IN LIVER 























Epidermal growth factor receptor (EGFR) plays a crucial role in hepatocyte proliferation. 
Its role in acetaminophen (APAP)-mediated hepatotoxicity and subsequent liver 
regeneration is completely unknown. We studied role of EGFR after APAP overdose 
using pharmacological inhibition strategy. Rapid, sustained and dose-dependent 
activation of EGFR was noted after APAP treatment in mice, which was triggered by 
glutathione depletion. EGFR activation was also observed in primary human 
hepatocytes after APAP treatment, preceding elevation of toxicity markers. Treatment of 
mice with an EGFR inhibitor (EGFRi), Canertinib, 1 hr post-APAP resulted in robust 
inhibition of EGFR activation and a striking reduction in APAP-induced liver injury. 
Metabolic activation of APAP, formation of APAP-protein adducts, APAP-mediated JNK-
activation and its mitochondrial translocation were not altered by EGFRi. However, 
EGFRi treatment prevented APAP-mediated mitochondrial dysfunction. Finally, delayed 
treatment with EGFRi, 12 hr post-APAP, did not alter peak injury but caused remarkable 
impairment of liver regeneration resulting in sustained injury and decreased survival 
after APAP overdose in mice. Impairment of liver regeneration was due to complete 
inhibition of cyclinD1 induction, subsequent phosphorylation of retinoblastoma protein 
and cell cycle arrest. In conclusion, our study has revealed a novel role of EGFR both in 
initiation of APAP injury and in stimulation of subsequent compensatory liver 









Epidermal growth factor receptor (EGFR) is a prototypical tyrosine kinase receptor of 
the ErbB family, which is highly expressed in liver and known to be involved in 
hepatocytes proliferation, liver regeneration and hepatocellular carcinogenesis 
(Michalopoulos and DeFrances 1997, Carver, Stevenson et al. 2002, Michalopoulos 
and Khan 2005). EGFR can be activated by variety of extracellular ligands, including 
EGF, transforming growth factor alpha (TGF-α), heparin-binding EGF (HB-EGF) and 
amphiregulin (Normanno, De Luca et al. 2006). Ligand binding leads to dimerization of 
EGFR and auto-phosphorylation of tyrosine residues in its cytoplasmic domain, which 
then act as a hub for numerous cell signaling pathways. Apart from hepatocyte growth 
factor (HGF), EGFR ligands are the only known direct mitogens which can cause 
hepatocyte proliferation in serum free medium, emphasizing an important role of EGFR 
in hepatocyte proliferation (Michalopoulos 2007). In vivo administration of EGFR ligands 
such as EGF and TGF-α also lead to hepatocyte proliferation along with increased liver 
size (Bucher, Patel et al. 1977). EGFR is activated very rapidly after 2/3rd partial 
hepatectomy (PH), and is known to play important role in promoting timely liver 
regeneration (Michalopoulos and Khan 2005, Michalopoulos 2007, Fausto, Campbell et 
al. 2012). Genetic deletion of EGFR in mice liver or shRNA-mediated downregulation of 
EGFR in rats resulted in delayed liver regeneration (Natarajan, Wagner et al. 2007, 
Paranjpe, Bowen et al. 2010). Further, mice deficient in EGFR ligands, amphiregulin 
and HB-EGF, displayed deficient liver regeneration and overexpression of HB-EGF 
increased liver regeneration (Michalopoulos and Khan 2005, Michalopoulos 2007, 
Fausto, Campbell et al. 2012). 
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Apart from the well-known role of EGFR in cell proliferation, its role in cell death 
signaling has also been reported, but remained largely ignored (Arany 2008, Reinehr 
and Haussinger 2009). Other than ligand-dependent activation of EGFR, ligand-
independent activation of EGFR by hydrophobic bile acids, CD95 ligand and 
hyperosmolarity has been reported in hepatocytes as well as hepatic stellate cells 
(HSCs), which was found to be involved in mediating cell death signaling (Reinehr, Graf 
et al. 2003, Reinehr, Schliess et al. 2003, Reinehr, Becker et al. 2004, Reinehr, Becker 
et al. 2005, Reinehr, Becker et al. 2005, Reinehr and Haussinger 2009, Sommerfeld, 
Reinehr et al. 2009, Reinehr and Haussinger 2012). An unexpected role of EGFR 
activation in cell death has also been reported in kidney (Arany 2008). Nephrotoxic 
insults such as cisplatin and cyclosporine A treatment were shown to activate EGFR in 
proximal tubular cells, which was involved in toxicity rather than survival (Arany, 
Megyesi et al. 2004, Sarro, Tornavaca et al. 2008).  
Acetaminophen (APAP) is the most commonly used analgesic worldwide and its 
overdose is the major cause of acute liver failure (ALF) in the western world, accounting 
for almost 50% of all the ALF cases. Current treatment options after APAP overdose are 
extremely limited with liver transplantation as the final resort (Bernal, Lee et al. 2015). 
APAP toxicity is initiated by metabolism to a reactive metabolite, N-acetyl-p-
benzoquinone imine (NAPQI), which then binds to cellular proteins (particularly 
mitochondrial proteins). This mitochondrial distress is exacerbated by a plethora of 
intracellular signaling events resulting in massive mitochondrial oxidative 
damage/dysfunction and liver cell necrosis (Jaeschke, McGill et al. 2012). Extensive 
research in the last few decades has revealed that APAP hepatotoxicity involves highly 
 
   
  
90
sophisticated pathways, but the exact intracellular signaling events are still not 
completely known (Jaeschke, McGill et al. 2012). Liver toxicity after APAP overdose is 
also followed by compensatory liver regeneration, which is a critical determinant of final 
recovery (Bhushan, Walesky et al. 2014). Identifying targets to stimulate liver 
regeneration holds great potential to develop novel therapeutic strategies (Hu and 
Colletti 2008, Donahower, McCullough et al. 2010, Bhushan, Walesky et al. 2014). 
Unfortunately, mechanisms of liver regeneration are mostly studied in PH model, which 
is considerably different from the APAP hepatotoxicity model.  
The role of EGFR in APAP-mediated acute liver injury and subsequent liver 
regeneration is completely unknown, which was investigated in the current study. Our 
work in chapter-II established an incremental dose model in mice to study mechanisms 
of liver regeneration after APAP-induced ALF. Paradoxically, dose-dependent activation 
of EGFR was observed after APAP overdose, such that activation of EGFR was 
remarkably greater at higher doses of APAP, where liver regeneration was inhibited. 
Here we report that early inhibition of EGFR activation by pharmacological intervention 
in mice remarkably attenuate APAP hepatotoxicity, delayed inhibition of EGFR 
activation lead to impaired compensatory liver regeneration, suggesting a dual role of 
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4.3 MATERIALS AND METHODS 
Animals, treatments and tissue harvesting  
Eight weeks old, C57BL/6J mice were purchased from Jackson Laboratories and used 
in all the studies. All animals were housed in Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC)-accredited facilities at the University 
of Kansas Medical Center under a standard 12-hr light/dark cycle with access to chow 
and water ad libitum. All studies were approved by The Institutional Animal Care and 
Use Committee at the University of Kansas Medical Center. For all APAP experiments, 
mice were fasted overnight and APAP (Sigma, St. Louis, MO) was dissolved in warm 
0.9% saline and administered intraperitoneally (i.p.) next morning. For study with 
incremental doses of APAP, mice (n = 3 to 7) were treated with either 300 or 600 mg/kg 
APAP, and sacrificed at 0, 0.25, 1, 3, 6, 12, 24, 72 and 96 hr following APAP treatment. 
For studies with EGFR inhibitor (EGFRi), canertinib, dihydrochloride salt (80 mg/kg, i.p.) 
(LC Laboratories, Woburn, MA) was dissolved in warm phosphate-buffered saline 
(PBS).  EGFRi or PBS (vehicle) was administered 1 or 12 hr after 300 mg/kg APAP and 
mice (n=3-12) were sacrificed at 3, 6, 12 and 24 hr or 24 and 48 hr after treatment with 
APAP, respectively (represented by scheme shown in Fig 4.4.2A and 4.4.8A).  For 
mitochondrial respiration analysis, EGFRi or PBS (vehicle) was administered 2 hr 
before or 1 hr after 300 mg/kg APAP and mice (n=3) were sacrificed at 1.5 hr or 3 hr 
after treatment with APAP, respectively (represented by scheme shown in Fig 4.4.5C 
and F).  For N-acetylcysteine (NAC) experiments, NAC (500 mg/kg, dissolved in PBS), 
EGFRi (80 mg/kg, i.p.) or PBS (vehicle) was administered 1.5 hr after APAP (300 
mg/kg, i.p.) and mice (n=3) were sacrificed 6 hr after treatment with APAP. For 
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glutathione depletion study, phorone (200 mg/kg, i.p., dissolved in corn oil) was 
administrated in mice (n=5) without fasting and mice were sacrificed 2 hr later. 
Euthanasia was performed by cervical dislocation under isoflurane anesthesia, and 
blood and livers were collected. Serum samples were obtained from the blood and used 
for further analysis. Liver sections were prepared for histological analysis as described 
previously (Wolfe, Thomas et al. 2011).   
Primary human hepatocytes (PHH) experiments 
Primary human hepatocytes (PHH) were isolated as described previously (Xie, McGill et 
al. 2014), without any modification, after informed consent of patient and study approval 
by University of Kansas Medical Center Institutional Review Board. Experiments were 
repeated 4 times, independently, with hepatocytes obtained from 4 liver donors. Cells 
were washed with sterile PBS, approximately 3 hr after seeding on collagen-coated 
dishes and treated with 10 mM APAP dissolved in serum free Hepatocyte Maintenance 
Medium (Lonza, Walkersvill, MD), supplemented as described previously (Xie, McGill et 
al. 2014). Cells were harvested at 0, 3, 6, 15, 24, 36 and 48 hr after treatment with 
APAP and used for further downstream analysis as described previously (Xie, McGill et 
al. 2014). 
Histological analysis and serum ALT measurement 
Paraffin-embedded liver sections (4 µm thick) were used for H&E staining and scored 
for percentage necrotic area. Serum alanine aminotransferase (ALT) was measured 
using the Infinity ALT kit (ThermoFisher Scientific, Pittsburgh, PA), according to the 
manufacturer’s protocol. 
 




Paraffin-embedded liver sections (4 µm thick) were used for immunohistochemical 
detection.  PCNA and nitrotyrosine staining were performed for cell proliferation analysis 
and for assessment of nitrotyrosine (NT) protein adducts, respectively, as described 
before (Wolfe, Thomas et al. 2011). Anti-PCNA antibody was purchased from Cell 
Signaling Technologies (Danvers, MA) and anti-nitrotyrosine antibody was purchased 
from Life Technologies (Grand Island, NY). Biotinylated secondary antibodies were 
purchased from Jackson Immunoresearch (West Grove, PA).  
Isolation of subcellular fractions, protein isolation and western blotting  
Total cell lysate was prepared from frozen liver tissues as described previously (Wolfe, 
Thomas et al. 2011). Mitochondria and cytosolic fractions were prepared from freshly 
isolated liver using differential centrifugation as described previously without any 
modification (Xie, Williams et al. 2013). Protein estimation and western blot analysis 
was performed using individual or pooled samples of protein extracts as previously 
described in detail (Wolfe, Thomas et al. 2011). All primary and secondary antibodies 
were obtained from Cell Signaling Technologies (Danvers, MA) unless stated otherwise. 
Anti-nitrotyrosine antibody was purchased from Upstate (Lake Placid, NY). Anti-APAP-
protein adduct antibody was a kind gift from Dr. Lance Pohl, NHIBL, NIH. Image J 
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Isolation of mitochondria from mouse liver and analysis of mitochondrial 
respiration 
Mitochondria were isolated from freshly obtained mice livers by differential 
centrifugation method. All the steps of the preparation were performed on ice. Briefly, 
the liver was rinsed 2X with mitochondria isolation buffer (MSHE+BSA: 70 mM sucrose, 
210 mM mannitol, 5 mM HEPES, 1 mM EGTA and 0.5% (w/v) fatty acid-free BSA; pH 
7.2) and minced using dounce homogenizer in ∼10 volumes of MSHE+BSA. 
Homogenate was centrifuged twice at 1000 g for 10 min at 4°C. The supernatant was 
passed through 2 layers of cheesecloth to remove fat/lipid layer. The supernatant was 
centrifuged at 8000 g for 10 min at 4°C. The pellet was washed once with MSHE+BSA 
and resuspended in a minimal volume of MSHE+BSA. Total protein (mg/ml) was 
determined using BCA protein assay. 
All mitochondrial respiration assays were performed using an XF24–3 Extracellular Flux 
Analyzer by Seahorse Bioscience (North Billerica, MA). The XF24 sensor cartridge was 
hydrated with 1 ml calibration buffer per well overnight at 37°C. Isolated liver 
mitochondria were first diluted ten times in cold Mitochondrial assay solution (1X MAS: 
70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM 
EGTA and 0.2% (w/v) fatty acid-free BSA, pH 7.2 at 37°C) with substrate (10 mM 
succinate + 2 µM rotenone), then subsequently diluted to 2 mg/ml and 50 µl of this 
mitochondrial suspension was plated to each well (except for background correction 
wells) while the plate was on ice. The plate was transferred to a centrifuge equipped 
with a swinging bucket and spun at 2000 g for 20 minutes at 4°C. After centrifugation, 
450 µl of 1X MAS + substrate (at room temperature) was added to each well. The 
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mitochondria were viewed briefly under a microscope to ensure consistent adherence to 
the well, then placed at 37°C for 10 minutes to allow the plate to warm. The sensor 
cartridge was loaded with port A, 40 mM ADP (4 mM final); port B, 25 µg/ml oligomycin 
(2.5 µg/ml final); port C, 40 µM FCCP (4 µM final); and port D, 40 µM antimycin A (4 µM 
final) to measure the bioenergetic profile. The plate was then transferred to the XF24 
instrument and the respiration was sequentially measured in a coupled state with 
substrate present (basal respiration), followed by State 3 (phosphorylating respiration, in 
the presence of ADP and substrate), State 4o (Leak state induced with the addition of 
oligomycin - inhibitor of ATP synthase), and then maximal uncoupler (FCCP)-stimulated 
respiration (State 3u). At the end, antimycin A (complex III inhibitor) is added to inhibit 
mitochondrial respiration completely. 
Glutathione (GSH and GSSG) analysis 
Total hepatic GSH and GSSG levels were measured in liver homogenates by kinetic 
assay with a modified method of Tietze and as described previously (Xie, 
Ramachandran et al. 2015). 
Statistical Analysis 
Data presented in the form of bar/line graphs show mean ± SEM. Significant difference 
between two groups was determined using Student’s t-test and between three or more 
groups using one-way analysis of variance (ANOVA) with Tukey's post-hoc test. 
Difference between groups was considered statistically significant at P<0.05.  
 
 




Rapid and sustained activation of EGFR in mice and primary human hepatocytes 
after APAP overdose  
Our work in chapter-II established an incremental dose model to study mechanisms of 
liver regeneration after APAP-induced ALF. Two separate groups of mice were 
administered either a ‘regenerating’ (300 mg/kg) or a “non-regenerating’ (600 mg/kg) 
dose of APAP, respectively. The lower dose caused extensive liver injury, followed by 
robust compensatory liver regeneration leading to recovery. In contrast, at higher dose, 
liver regeneration was inhibited leading to sustained injury and decreased survival. 
EGFR signaling is considered crucial for hepatocyte proliferation. Paradoxically, 
activation of EGFR was remarkably greater at the higher dose of APAP, where liver 
regeneration was inhibited. To further follow up, in the current study, activation of EGFR 
was examined after incremental doses of APAP (300 mg/kg and 600 mg/kg) in mice 
over an extended time-course of 15 min to 96 hr (Fig. 4.4.1A and B). A striking increase 
in phosphorylation of EGFR at the Tyr-1068 residue (i.e. activation) was observed within 
15 minutes after treatment with 300 mg/kg APAP and was sustained up-to 96 hr, with 
peak activation at around 6 hr. Overall activation of EGFR was remarkably higher after 
treatment with 600 mg/kg APAP up to 24 hr, with peak activation at 3 hr, but both EGFR 
expression and phosphorylation were significantly downregulated from 24 to 96 hr at the 
higher dose. On the contrary, EGFR activation remained sustained at the lower dose 
and was greater compared to the higher dose after 24 hr (Fig. 4.4.1A and B).  
Remarkable liver injury, as indicated by elevation of serum ALT levels, was observed 
beyond 3 hr after treatment with both doses of APAP, suggesting activation of EGFR  
 




Figure 4.4.1. Rapid and sustained activation of EGFR in mice and primary human 
hepatocytes after APAP-treatment. (A) Western blot analysis of phospho-EGFR (Tyr1068) 
and EGFR in total cell lysate and (C) ALT levels in serum, at various time points after 
administration of 300 mg/kg and 600 mg/kg APAP in mice (n=3-7). (B) Densitometric analysis 
showing activation (phosphorylation) of EGFR based on western blot image shown in (A). (D)  
Western blot analysis of phospho-EGFR and EGFR in total cell lysate at various time points 
after treatment of primary human hepatocytes (PHH) with 10 mM APAP. (E) Densitometric 
analysis showing activation of EGFR in PHH with data representing mean ± SEM of 
independent western blot analysis from 4  liver donors.  * indicate significant difference between 
groups at p<0.05. 
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preceded liver injury in mice (Fig. 4.4.1C).  As reported in chapter-II, injury was 
sustained at 72 and 96 hr in the higher dose group, but mice treated with lower dose 
recovered at these time points (Fig. 4.4.1C).                    
We also examined EGFR activation in primary human hepatocytes (PHH) following 
APAP treatment. PHH were cultured in serum free hepatocyte maintenance medium 
without any addition of EGFR ligands or any other primary mitogens and were treated 
with 10mM APAP for various time points from 0 to 48 hr. Similar to the mouse data, 
significant EGFR activation was observed in PHH starting as early as 3 hr (about 20-
fold activation at this time point) and activation remained sustained up to 48 hr, with 
peak activation observed at 24 hr (Fig. 4.4.1D and E). Previous studies have also 
shown that earliest signs of mitochondrial damage i.e. loss of mitochondrial membrane 
potential occurs between 6 and 15 after APAP treatment (Xie, McGill et al. 2014). These 
data indicate that EGFR activation occurs very rapidly after a toxic dose of APAP, both 
in mice and PHH, preceding development of injury.   
Dramatic attenuation of APAP hepatotoxicity by pharmacological inhibition of 
EGFR (1 hr post-APAP)    
Next, the role of EGFR activation in APAP-induced liver injury was investigated. Mice 
were treated with the highly potent and selective pan-EGFR inhibitor (canertinib, 80 
mg/kg) (Slichenmyer, Elliott et al. 2001),1 hr after administration of APAP, and an 
extended time-course of 3 to 24 hr after APAP was examined (as represented by 
scheme shown in Fig 4.4.2A). APAP treatment caused significant liver necrosis in the 
centrilobular region and elevation of serum ALT levels, with injury progressing with time  
 




Figure 4.4.2. Treatment with EGFR inhibitor (1 hr post-APAP) remarkably attenuated 
APAP-induced hepatotoxicity. (A) Schematic showing experimental design. (B) 
Representative photomicrographs of H&E stained liver sections, (C) serum ALT levels and (D) 
percentage necrosis area based on H&E stained liver sections of mice (n=3-12) treated with 
300 mg/kg APAP followed by canertinib (80 mg/kg) or PBS, 1 hr post-APAP. All samples were 
collected at various time points up-to 24 hr after APAP treatment. * indicate significant 
difference between groups at p<0.05. 
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from 3 to 24 hr (Fig. 4.4.2B-D). Treatment with EGFR inhibitor (EGFRi) caused a 
dramatic reduction of the area of necrosis, with almost no observable necrosis up to 12 
hr and very small zones of necrosis at 24 hr (Fig. 4.4.2B and D). A similar trend was 
also observed for serum ALT levels at all the investigated time points (Fig. 4.4.2C). As 
expected, APAP treatment caused significant activation of EGFR and treatment with 
EGFRi decreased EGFR activation to basal levels (Fig. 4.4.3A). This dramatic effect 
with almost complete abolishment of liver injury after pharmacological inhibition of 
EGFR activation suggested crucial role of EGFR in APAP-induced hepatotoxicity. 
EGFR inhibition does not alter APAP-mediated glutathione depletion and APAP-
protein binding   
Next, we investigated several major steps involved in the development of APAP toxicity 
to determine the mechanisms of EGFRi-mediated reduction in APAP toxicity. APAP 
metabolism in liver results in its bio-activation by formation of a reactive metabolite, 
NAPQI. NAPQI is conjugated with glutathione in the liver, followed by excretion of the 
conjugated product. This results in rapid depletion of glutathione and binding of excess 
NAPQI to cellular proteins (especially mitochondrial proteins) leading to formation of 
APAP-protein adducts (Jaeschke, McGill et al. 2012). APAP caused significant 
depletion of glutathione when measured at 3 hr after APAP administration, which was 
not altered by treatment with EGFRi (1 hr post-APAP) (Fig. 4.4.3B). Recovery of 
glutathione levels after initial depletion can regulate progression of injury by decreasing 
APAP-induced oxidative stress. Recovery of glutathione levels at later time points (6 to 
24 hr) was not increased by EGFRi treatment (Fig. 4.4.3B). Further, APAP-protein  
 





Figure 4.4.3. Robust inhibition of EGFR activation without any alteration of APAP 
metabolism and protein-adduct formation by EGFR inhibitor. (A) Western blot analysis of 
phospho-EGFR and EGFR, (B) total glutathione levels in liver extract; APAP-protein adducts 
levels as measured by (C) western blot analysis and (D) HPLC-MS/MS. Mice (n=3-5) were 
treated with 300 mg/kg APAP followed by canertinib (80 mg/kg) or PBS, 1 hr post-APAP. All 
samples were collected at various time points up-to 24 hr after APAP treatment.   
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adduct levels were measured by both western blot analysis (Fig. 4.4.3C)  and HPLC 
based method (Fig. 4.4.3D). No significant difference was observed in APAP-protein 
adduct levels by treatment with EGFRi. These data indicate that EGFRi treatment does 
not alter early injury initiation events of APAP toxicity, namely, metabolic activation of 
APAP to reactive metabolite NAPQI, subsequent glutathione depletion and APAP-
protein adducts formation. 
JNK activation, its mitochondrial translocation and signaling through PKC not 
altered by EGFR inhibition 
APAP-protein adducts formation is very crucial for initiation of APAP toxicity, but not 
sufficient to cause hepatocyte death and necrosis (Jaeschke, McGill et al. 2012). Initial 
mitochondrial distress is exacerbated by a plethora of intracellular signaling events, 
which are still under investigation. JNK is considered one of the important mediators of 
APAP toxicity and can be potentially activated by EGFR signaling. Phosphorylation 
mediated activation of JNK and its mitochondrial translocation is known to exacerbate 
mitochondrial oxidative stress during APAP toxicity (Jaeschke, McGill et al. 2012). As 
expected, APAP treatment caused remarkable activation (phosphorylation) of JNK at 3 
and 6 hr followed by rapid decrease in activation at 12 hr, when examined using total 
cell lysate. Interestingly, EGFRi treatment did not alter APAP-mediated JNK activation 
(Fig. 4.4.4A). We further investigated mitochondrial levels of JNK and p-JNK. 
Mitochondrial translocation of JNK and increase in mitochondrial levels of activated JNK 
were observed at 3 and 6 hr after APAP treatment, which was not decreased by 
treatment with EGFRi. In fact, mitochondrial levels of p-JNK were significantly higher in  
 




Figure 4.4.4. JNK activation, its mitochondrial translocation and signaling through PKC 
not altered by EGFR inhibition. Western blot analysis of p-JNK and JNK in (A) total cell lysate 
and (B) mitochondrial fraction with densitometric analysis of mitochondrial activated JNK shown 
in (C). (D) Western blot analysis showing PKC activation (studied using antibody against 
phosphorylated PKC substrates in mitochondria) with its densitometric analysis shown in (E). All  
analysis were done on liver samples collected at various time points after treatment with 300 
mg/kg APAP + PBS or APAP +  canertinib (80 mg/kg, 1 hr post-APAP) (n=3-4). * indicate 
significant difference between groups at p<0.05.   
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EGFRi treated group compared vehicle-treated control at 6 hr after APAP (Fig. 4.4.4B 
and C). Recently, protein kinase C (PKC) was reported to phosphorylate mitochondrial 
proteins and regulate APAP-induced liver injury in JNK-dependent and independent 
manner (Saberi, Ybanez et al. 2014). As PKC is one of the downstream effector of 
EGFR, we investigated if EGFR inhibition can alter APAP-mediated PKC activation. 
Consistent with the previous report, activation of PKC signaling (as studied by 
measuring phosphorylated PKC substrates in mitochondria) was observed at 3 and 6 hr 
after APAP administration and was not altered by EGFRi treatment (Fig 4.4.4D and E).  
APAP caused mitochondrial translocation of EGFR and mitochondrial 
dysfunction, which was restored by EGFR inhibitor 
EGFR has been reported previously to translocate to mitochondria, in endocytosis 
dependent manner. EGFR-mediated phosphorylation was reported to cause alteration 
of mitochondrial electron transport chain and subsequently mitochondrial function 
(Boerner, Demory et al. 2004, Demory, Boerner et al. 2009). Interestingly, in our study, 
EGFR levels increased remarkably in mitochondria at 1.5 hr after treatment with APAP 
in mice, suggesting APAP-mediated translocation of EGFR to mitochondria (Fig. 
4.4.5A). Similar mitochondrial translocation was also observed for activated EGFR after 
APAP treatment. Further, mitochondrial translocation of both EGFR and activated 
EGFR was completely abolished by pretreatment with EGFRi (2 hr prior to APAP) (Fig. 
4.4.5A). Our results were corroborated in PHH, where remarkable translocation of 
EGFR into mitochondria was observed at 6 and 15 hr after APAP treatment, along with 
a similar increase in mitochondrial levels of activated EGFR (which was more evident at 
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15 hr) (Fig. 4.4.5B). Our results coincide with previous observations, where 
mitochondrial dysfunction was found to be initiated between 6 and 15 hr after APAP 
treatment in PHH (Xie, McGill et al. 2014).   
Next, we investigated the effect of EGFR inhibition on alteration of APAP-mediated 
mitochondrial dysfunction using Seahorse extracellular flux analyzer. Oxygen 
consumption parameters were analyzed in freshly isolated mitochondria 1.5 hr after 
treatment with APAP in mice with or without EGFRi (2 hr prior to APAP) (as represented 
by scheme shown in Fig 4.4.5C). Significant reduction in ADP-stimulated 
phosphorylating mitochondrial respiration and FCCP (uncoupler)-induced maximal 
mitochondrial respiration was observed within 1.5 hr after APAP administration. 
Interestingly, EGFRi treatment completely restored both these parameters (Fig. 4.4.5D 
and E). Similar restoration of mitochondrial functional parameters was observed at 3 hr 
after APAP treatment in mice when EGFR inhibitor was administered 1 hr post-APAP 
(Fig. 4.4.5F, G and H). These data indicate that mitochondrial translocation of EGFR 
and its activity in mitochondria may be involved in early mitochondrial dysfunction after 
APAP overdose preceding overt necrosis, which was prevented by treatment with the 
EGFR inhibitor.  
Decreased oxidative stress, mitochondrial protein nitration and release of 
endonucleases from mitochondria by EGFR inhibitor 
Initial mitochondrial dysfunction leads to a vicious circle of mitochondrial oxidative and 
nitrosative-stress and subsequent mitochondrial damage during APAP-induced liver 
 




Figure 4.4.5. APAP caused mitochondrial translocation of EGFR and mitochondrial dysfunction, which was 
restored by EGFR inhibitor. Western blot analysis of phospho-EGFR and EGFR in mitochondrial fraction at various 
time points, (A) after administration of APAP (300 mg/kg) in mice pretreated (2hr prior to APAP) with canertinib (80 
mg/kg); (B) after treatment of primary human hepatocytes (PHH) with 10 mM APAP. (C-H) Oxygen consumption rate 
analysis in freshly isolated mitochondria from mice (n=3) treated with APAP (300 mg/kg) + PBS, APAP (300 mg/kg) + 
canertinib (80 mg/kg) or without any treatment (control), using Seahorse extracellular flux analyzer. (D) and (E) 
Canertinib was administered 2hr before APAP and analysis was done 1.5 hr after APAP treatment, as represented by 
scheme in (C). (G) and (H) Canertinib was administered 1hr post-APAP and analysis was done 3 hr after APAP 
treatment, as represented by scheme in (F) . OXPHOS was manipulated with injection of ADP (4 mM), oligomycin 
(2.5 µg/ml), FCCP (4 µM), and antimycin A (4 µM). Respiration was sequentially measured in a coupled state with 
substrate present (basal respiration), followed by State 3 (phosphorylating respiration, in the presence of ADP and 
substrate), State 4o (induced with the addition of oligomycin), and then maximal uncoupler-stimulated respiration 
(State 3u). * indicate significant difference w.r.t. to APAP+PBS group at p<0.05.              
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necrosis (Jaeschke, McGill et al. 2012). Oxidized glutathione levels and its percentage 
with respect to total glutathione levels (marker of oxidative stress) were measured at 
various time points after treatment with APAP with and without EGFRi. A significant 
decrease in oxidized glutathione levels (Fig. 4.4.6A) and the percentage of oxidized 
glutathione (Fig. 4.4.6B) was observed in EGFRi-treated group compared to vehicle-
treated group at 12 and 24 hr after APAP-treatment. Superoxide radicals react with 
nitric oxide to form the potent oxidant peroxynitrite, which is generated mainly in 
mitochondria during APAP hepatotoxicity (Jaeschke, McGill et al. 2012). Peroxynitrite 
then reacts with tyrosine residues of proteins to form nitrotyrosine protein adducts, 
which further results in mitochondrial damage. Staining liver sections using nitrotyrosine 
antibody revealed significant reduction in APAP-mediated formation of nitrotyrosine 
adducts at 6 hr after treatment with EGFRi (Fig. 4.4.6C). Further, western blot analysis 
of mitochondrial fraction revealed that APAP-mediated nitrotyrosine adducts formation 
was significantly reduced in mitochondria after treatment with EGFRi (Fig. 4.4.6D and 
E). Mitochondrial dysfunction and oxidative damage ultimately lead to opening of 
mitochondrial permeability transition (MPT) pore and release of endonucleases such as 
apoptosis-inducing factor (AIF) and endonuclease G from mitochondrial intermembrane 
into the cytosol. These endonucleases cause DNA damage that ultimately results in 
liver necrosis (Jaeschke, McGill et al. 2012). As expected, APAP treatment caused 
remarkable release of mitochondrial intermembrane endonucleases, AIF and 
endonuclease G, as well as SMAC into the cytosol (Fig. 4.4.6F-G). EGFR inhibition 
completely abolished release of AIF at 3 hr after APAP-treatment and cytosolic AIF 
remained very low even at 6 hr (Fig. 4.4.6F-G). Similarly, significant decrease in early  
 




Figure 4.4.6. Decreased oxidative stress, mitochondrial protein nitration and release of 
endonucleases from mitochondria by EGFR inhibitor. (A) Oxidized glutathione levels and 
(B) percentage of oxidized glutathione with respect to total glutathione level in total liver extract. 
(C) Representative photomicrographs of liver sections stained for nitrotyrosine-protein adducts. 
(D) Western blot analysis of nitrotyrosine adducts in mitochondrial fraction with its densitometric 
analysis shown in (E). (F) Western blot analysis of AIF, endonuclease G and SMAC in cytosolic 
fraction with densitometric analysis of AIF as shown in (G). All  analysis were done on liver 
samples collected at various time points after treatment with APAP (300 mg/kg) + PBS or APAP 
(300 mg/kg)  +  canertinib (80 mg/kg, 1 hr post-APAP) (n=3-5). * indicate significant difference 
between groups at p<0.05. 
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release of endonuclease G was observed after EGFRi treatment (Fig. 4.4.6F). These 
data suggest that EGFR plays an important role in development of mitochondrial 
oxidative stress and mitochondrial damage during pathogenesis of APAP hepatotoxicity.   
Role of glutathione depletion in rapid activation of EGFR by toxic dose of APAP 
Early activation of EGFR was observed after APAP treatment, even in primary human 
hepatocytes, when cultured in chemically defined serum free medium with no EGFR 
ligands or other primary mitogens. This suggested a possible role of ligand-independent 
intercellular events in triggering of EGFR activation, as reported previously in liver cells 
after other toxic insults (Reinehr and Haussinger 2009). Glutathione depletion is one of 
the earliest events after APAP overdose. In order to investigate if glutathione depletion, 
per se, can cause activation of EGFR, mice were treated with phorone (200 mg/kg, i.p.), 
a glutathione depleting agent. As expected, phorone treatment caused remarkable 
depletion of glutathione within 2 hr (Fig. 4.4.7A). Interestingly, glutathione depletion by 
treatment with phorone was accompanied by robust activation of EGFR and 
downregulation of EGFR (Fig. 4.4.7B and C).  To further substantiate the role of 
glutathione depletion in activation of EGFR after APAP overdose, APAP-mediated 
depleted glutathione was replenished by treatment with NAC (N-acetylcysteine, 500 
mg/kg, i.p.), 1.5 hr after APAP (Fig. 4.4.7D). Treatment with NAC caused remarkable 
decrease in APAP-mediated EGFR activation, as analyzed 6 hr after APAP treatment, 
correlating with recovery of glutathione levels (Fig. 4.4.7E and F). These data suggest 
that glutathione depletion after APAP overdose may be involved in early activation of 
EGFR.    
 




Figure 4.4.7. Role of glutathione depletion in rapid activation of EGFR by APAP. (A) Total 
glutathione levels in liver extract and (B) western blot analysis of phospho-EGFR and EGFR in 
total cell lysate from liver samples obtained 2 hr after treatment with Phorone (200 mg/kg in corn 
oil) or corn oil (control) in mice (n=5).  (C) Densitomertic analysis showing EGFR activation 
based on western blot image shown in (B).  (D) Total glutathione levels in liver extract  and (E) 
western blot analysis of phospho-EGFR and EGFR in total cell lysate from liver samples 
obtained 6 hr after treatment with APAP (300 mg/kg) + PBS or APAP (300 mg/kg) + NAC (N-
acetylcysteine: 500 mg/kg, 1.5 hr post-APAP) in mice (n=3). (F) Densitomertic analysis showing 
EGFR activation based on western blot image shown in (E). * indicate significant difference 
between groups at p<0.05. 
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Increased progression of injury, impaired recovery and decreased survival after 
delayed treatment with EGFR inhibitor (12 hr post-APAP) 
Several studies using partial hepatectomy (PH) model have demonstrated a crucial role 
of EGFR signaling in liver regeneration after liver re-section (Michalopoulos 2007, 
Fausto, Campbell et al. 2012). Thus, the role of EGFR activation was investigated in 
compensatory liver regeneration after APAP-induced liver injury. Since liver 
regeneration is a compensatory response to liver injury after APAP toxicity, any 
alteration in liver injury can indirectly affect regeneration. To investigate a direct role of 
EGFR on liver regeneration, EGFRi was administered 12 hr post-APAP, with notion that 
injury is already established by this time and liver regeneration is just initiated based on 
previously characterized dynamics of liver injury and regeneration after APAP overdose 
(as described in chapter-II) . Parameters related to liver injury and regeneration were 
studied at 24 and 48 hr after treatment with APAP (as represented by the scheme 
shown in Fig 4.4.8A). As expected, liver injury at 24 hr after APAP treatment was not 
altered by EGFRi-treatment as indicated by percentage necrotic area (Fig. 4.4.8B and 
D) and serum ALT levels (Fig. 4.4.8C). Similar to our results in chapter-II, the injury was 
significantly resolved at 48 hr compared to 24 hr in APAP-treated group. However, liver 
injury did not improve at 48 hr compared to 24 hr in EGFRi-treated group (Fig. 4.4.8B-
D) and resulted in 50% decrease in survival at 48 hr post-APAP (Fig. 4.4.8E).   
 




Figure 4.4.8. Increased progression of injury, impaired recovery and decreased survival 
after delayed (12 hr post-APAP) treatment with EGFR inhibitor. (A) Schematic showing 
experimental design. (B) Representative photomicrographs of H&E stained liver sections, (C) 
serum ALT levels, (D) percentage necrosis area based on H&E stained liver sections and (E) 
survival analysis of mice treated with 300 mg/kg APAP followed by treatment with canertinib (80 
mg/kg) or PBS, 12 hr post-APAP. All samples were collected and survival was recorded at 24 
and 48 hr after APAP treatment (n=5-6). * indicate significant difference between groups at 
p<0.05. # indicates significant difference w.r.t. 24 hr time point within same treatment group.  
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Impaired liver regeneration by delayed treatment with EGFR inhibitor (12 hr post-
APAP) 
Next, we investigated effect of delayed treatment with EGFRi on compensatory liver 
regeneration following APAP overdose. Liver regeneration was studied using PCNA 
staining (Fig. 4.4.9A), which is a marker of cell proliferation. Consistent with our results 
in chapter-II, numerous PCNA-positive cells were observed surrounding the zones of 
necrosis, at 24 and 48 hr after treatment with APAP, suggesting robust liver 
regeneration. Interestingly, minimal PCNA-positive cells were observed at both time 
points in the EGFRi group, indicating compensatory liver regeneration response was 
almost completely abolished after treatment with EGFRi (Fig. 4.4.9A and B). 
Quantification of PCNA-positive cells was further corroborated by analysis of PCNA 
protein expression using western blot (Fig. 4.4.10A and E). 
Cell cycle regulators correlated with impaired liver regeneration by delayed 
treatment with EGFR inhibitor (12 hr post-APAP) 
Induction of Cyclin D1 is a key initial step that regulates entry into the cell cycle. APAP-
treatment caused a remarkable increase in the expression of Cyclin D1 at 24 and 48 hr. 
APAP-mediated increase in protein expression of CyclinD1 was dramatically decreased 
at both time points after delayed treatment with EGFRi (Fig. 4.4.10A and B).  Cyclin D1 
binds to CDK4 and causes its activation, which then phosphorylates Rb protein, 
ultimately leading to induction of several key cell cycle genes. CDK4 protein expression 
followed a pattern similar to Cyclin D1 in both groups (Fig. 4.4.10A and C). Further, 
remarkable phosphorylation of Rb protein was observed at 48 hr in APAP-treated 
 




Figure 4.4.9. Impaired liver regeneration by delayed (12 hr post-APAP) treatment with 
EGFR inhibitor. (A) Representative photomicrographs of PCNA stained liver sections with 
arrows indicating cells in S-phase with nuclear PCNA staining (brown). (B) Total number of 
PCNA-positive cell per high power field (x40). Mice (n=3-5) were treated with 300 mg/kg APAP. 
Canertinib (80 mg/kg) or PBS was administered 12 hr post-APAP. All samples were collected at 
24 and 48 hr after APAP treatment. * indicate significant difference between groups at p<0.05. 
 
 




Figure 4.4.10. Cell cycle regulators correlated with impaired liver regeneration after 
delayed treatment with EGFR inhibitor (12 hr post-APAP). (A) Western blot analysis of 
cyclinD1, CDK4, phospho-Rb and PCNA using total liver extract with their densitometric 
analysis shown in (B), (C), (D) and (E), respectively. Mice (n=3-4) were treated with 300 mg/kg 
APAP. Canertinib (80 mg/kg) or PBS was administered 12 hr post-APAP. All samples were 
collected at 24 and 48 hr after APAP treatment. * indicate significant difference between groups 
at p<0.05.  
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group, which was completely abolished after treatment with EGFRi (Fig. 4.4.10 A and 
D). These data demonstrate that delayed treatment with EGFRi (12 hr post-APAP) 
prevented cell cycle progression and caused complete inhibition of liver regeneration 




















Although mechanisms of APAP hepatotoxicity have been extensively studied leading to 
considerable progress in our knowledge, the exact intracellular signaling events still not 
completely known (Jaeschke, McGill et al. 2012). On the contrary, mechanisms of 
compensatory liver regeneration that follows liver injury after APAP overdose have just 
begun to be explored. EGFR signaling is well known to play critical role in hepatocyte 
proliferation and normal liver regeneration after PH (Michalopoulos 2007, Fausto, 
Campbell et al. 2012), but a few reports also suggest its role in cell death signaling in 
liver (Arany 2008, Reinehr and Haussinger 2009). The role of EGFR in acetaminophen 
(APAP)-mediated acute liver injury and subsequent liver regeneration is completely 
unknown, which was investigated in this study.      
Similar to our work in chapter II, dose-dependent activation of EGFR was observed after 
toxic doses of APAP in mice such that activation was remarkably greater at a higher 
non-regenerating dose of APAP. Interestingly, EGFR activation starts very rapidly, 
within 15 min. after APAP treatment. Similar rapid and consistent activation of EGFR 
was also observed in primary human hepatocytes after APAP treatment. This dose-
dependent early activation of EGFR, preceding injury, with paradoxical inverse 
correlation with liver regeneration, suggested a possible role of EGFR activation in the 
development of injury. Indeed, inhibition of EGFR both pre- and post-APAP treatment 
by using a highly specific pan-EGFR inhibitor (Slichenmyer, Elliott et al. 2001), 
canertinib, almost completely abolished APAP toxicity consistently and reproducibly, 
suggesting a crucial role of EGFR activation in APAP hepatotoxicity. This paradoxical 
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role of EGFR activation in cell death is not completely unprecedented. Hydrophobic bile 
acids and CD95 ligand have been previously reported to activate EGFR in both 
hepatocytes and HSCs (Reinehr, Graf et al. 2003, Reinehr, Schliess et al. 2003, 
Reinehr, Becker et al. 2004, Reinehr, Becker et al. 2005, Reinehr, Becker et al. 2005, 
Reinehr and Haussinger 2009, Sommerfeld, Reinehr et al. 2009, Reinehr and 
Haussinger 2012).  EGFR activation in these studies was involved in apoptosis through 
tyrosine phosphorylation of death receptor (CD95) and stabilization of the death-
inducing signaling complex and inhibition of EGFR activation resulted in decreased cell 
death (Reinehr and Haussinger 2012). Similarly, EGFR was activated after treatment 
with the nephrotoxic insults cisplatin and cyclosporine A in proximal renal tubular cell 
lines and inhibition of EGFR activation resulted in diminished cell death (Arany, Megyesi 
et al. 2004, Sarro, Tornavaca et al. 2008).  
We further investigated the potential mechanisms underlying role of EGFR activation in 
mediating APAP hepatotoxicity. Metabolic activation of APAP, reactive metabolite-
mediated glutathione depletion and subsequent covalent binding to cellular proteins 
were not altered by EGFRi treatment indicating that the early events involved in 
initiation of APAP hepatotoxicity were not changed by EGFRi treatment. Initial 
mitochondrial dysfunction and its feed-forward accentuation by oxidative stress play a 
central role in APAP hepatotoxicity with underlying signaling pathways not completely 
known (Jaeschke, McGill et al. 2012). Our study revealed, for the first time, that EGFR 
translocated to mitochondria and its activated form is increased in mitochondria very 
rapidly after APAP treatment. This was associated with very early decline in 
mitochondrial respiratory capacity, preceding overt necrosis after APAP overdose. 
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Mitochondrial levels of both activated EGFR and EGFR, were drastically decreased by 
EGFR inhibition, resulting in complete restoration of mitochondrial function. 
Subsequently, EGFR inhibition also prevented mitochondrial oxidative stress and 
release of mitochondrial intermembrane proteins, especially AIF, into the cytosol, which 
is important for nuclear DNA damage and necrosis. These data have revealed a highly 
novel role of EGFR in APAP toxicity via modulating mitochondrial dysfunction. The 
exact mechanisms how mitochondrial EGFR activity can be involved in very early 
mitochondrial dysfunction remain unknown. EGFR can be involved, directly or indirectly 
via one of its effectors, in phosphorylation or alteration of mitochondrial proteins 
involved in APAP-associated mitochondrial dysfunction such as Sab. A previous study 
reported that activated EGFR can be translocated to mitochondria and phosphorylate 
mitochondrial cytochrome c oxidase subunit II (CoxII) leading to decrease in its activity 
and ATP depletion (Demory, Boerner et al. 2009). Further detailed studies are 
necessary to determine the exact interacting proteins of EGFR in mitochondria during 
APAP hepatotoxicity.  
The mechanism of rapid activation of EGFR is another interesting aspect which was 
investigated in this study. Early activation of EGFR in primary human hepatocytes in 
maintenance medium, where no EGFR ligands were present, suggested a possible role 
of ligand-independent intracellular mechanism in activation of EGFR. Such a 
mechanism has been demonstrated in liver cells after apoptotic-stimuli and was 
specifically involved in cell death (Reinehr and Haussinger 2009). These studies also 
demonstrated that oxidative stress was responsible for phosphorylation of EGFR via 
activation of Yes kinase (Reinehr and Haussinger 2009). In our study, investigations 
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with the glutathione depleting agent (phorone) and glutathione replenishing agent (NAC) 
indicated a potential role of glutathione depletion in EGFR activation. This is in 
concordance with the fact that glutathione depletion is one of the very early events that 
occur after APAP overdose similar to EGFR activation and glutathione is required 
physiologically to scavenge ROS and limit oxidative stress. The role of GSH depletion in 
EGFR activation is supported by rapid activation of EGFR in serum free conditions 
where no EGFR ligands are present. However, our studies do not rule out possibility of 
ligand-dependent activation of EGFR after APAP overdose, especially at later time 
points. TGF-α can be produced by hepatocytes and activate EGFR receptor on 
hepatocytes in an autocrine fashion (Michalopoulos and Khan 2005). Whether this 
autocrine loop by de novo TGF-α synthesis may be involved in activation of EGFR 
remains to be tested.  
In order to investigate a direct role of EGFR activation on liver regeneration after APAP 
overdose, a delayed EGFRi treatment strategy (12 hr post-APAP) was utilized, such 
that APAP hepatotoxicity was already established. Delayed treatment with EGFRi 
almost completely abolished compensatory hepatocyte proliferation after APAP 
overdose. Failure of cell cycle progression was due to complete inhibition of cyclin D1 
induction. This suggested that apart from the role in liver injury after APAP overdose, 
EGFR signaling plays a critical function in liver regeneration as well. Similarly, a dual 
role of EGFR was reported previously in HSCs, where activation of EGFR upon 
stimulation with bile acids caused cell proliferative signaling, which shifted to cell death 
signaling upon sustained JNK activation-mediated coupling of EGFR with the CD95 
death receptor (Reinehr and Haussinger 2009, Sommerfeld, Reinehr et al. 2009). A 
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similar dual role of EGFR has been proposed in the case of nephrotoxic insults, where 
EGFR activation can lead to renal injury or recovery depending on degree, duration and 
type of stress (Arany 2008). A number of previous studies in the PH model of liver 
regeneration show that inhibition or elimination of a single pathway (including EGFR 
signaling) can only delay or diminish liver regeneration but cannot permanently abolish 
liver regeneration due to upregulation of compensatory pathways (Michalopoulos 2007). 
In contrast, in our study, delayed inhibition of EGFR after APAP overdose resulted in 
almost complete inhibition of liver regeneration, resulting in progression of injury and 
decreased survival. These data suggest that the dynamics of liver regeneration is very 
different in the APAP-induced ALF model (compared to PH), which advances very 
rapidly and involves progression of injury, such that a timely regenerative response is 
imminently critical for final recovery. Since most of these studies so far have been 
focused on studying mechanisms of liver regeneration after PH, there is a critical need 
to understand mechanisms of liver regeneration in acute liver injury models, which are 
more relevant for clinical drug-induced ALF.   
Our data regarding deleterious effect of EGFR inhibition on liver regeneration suggest 
that it will be challenging to develop EGFR inhibition as a therapeutic strategy for APAP 
toxicity as depending upon the time of inhibition, outcome can be completely opposite. 
This is particularly important aspect to consider in case of APAP overdose, where the 
exact time of overdose is not usually known in patients. Further comprehensive studies 
in future, to investigate temporal dynamics of signaling pathways affected by EGFR 
activation during pathogenesis of APAP hepatotoxicity can assist in delineating toxicity 
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effectors from regenerative signaling for targeted development of anti-injury or pro-
regenerative therapy.  
To conclude, early inhibition of EGFR activation after APAP overdose in mice 
attenuated liver injury by preventing mitochondrial dysfunction and delayed inhibition of 
EGFR resulted in impairment of liver regeneration after APAP toxicity by arresting cell 
cycle activation. Thus our study indicated that EGFR activation can play a dual role in 
APAP overdose and is involved in both initiation of APAP-induced injury and in 
stimulating subsequent liver regeneration. Further, our study supports the emerging 
notion that signaling pathways that regulate liver injury and subsequent tissue repair are 
intricately linked and similar to death receptors, growth factor receptor such as EGFR 





































   
  
124
Acetaminophen (APAP) overdose is the leading cause of acute liver failure (ALF) in the 
western world, accounting nearly 50% of all the ALF cases in the US and 60% in the UK 
(Bernal and Wendon 2013, Bernal, Lee et al. 2015). Despite decades of research, 
current treatment options after APAP-overdose are extremely limited.  N-acetylcysteine 
(NAC) is the current standard of care for APAP overdose patients, which is effective 
only at an early stage (Athuraliya and Jones 2009, Bernal, Lee et al. 2015). 
Mechanisms of liver injury after APAP overdose have been extensively investigated in 
past in order to develop novel therapeutic strategies. However, most of the patients 
seek medical attention late, such that injury is already established and difficult to treat 
(Larson 2007). Liver injury after APAP-overdose is subsequently followed by 
compensatory liver regeneration, which promotes recovery. Previous studies have 
demonstrated that liver regeneration is a critical determinant of survival after APAP 
overdose (Schmidt and Dalhoff 2005, Hu and Colletti 2008, Apte, Singh et al. 2009, 
Donahower, McCullough et al. 2010). Liver regeneration can be potentially modulated 
even at a late stage in the pathogenesis of APAP-induced ALF and stimulating liver 
regeneration in patients of APAP-induced ALF holds a great therapeutic potential. 
However, development of novel regenerative therapies for ALF is hampered because 
the mechanisms of liver regeneration after APAP-induced ALF have not extensively 
explored yet. The mechanisms of liver regeneration are mostly studied in the partial 
hepatectomy (PH) model (Michalopoulos 2007), which is considerably different from 
APAP-hepatotoxicity, the model of clinical ALF.  The focus of the studies outlined in this 
dissertation was to investigate the mechanisms of liver regeneration after APAP-
induced liver injury. After initial studies to establish a model to identify potential 
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regulators of liver regeneration after APAP overdose in mice, our later studies were 
focused on investigating the role of β-catenin, GSK3 and EGFR in liver regeneration 
after APAP-induced liver injury.  
5.1 INCREMENTAL DOSE MODEL TO STUDY LIVER REGENERATION AFTER 
APAP OVERDOSE IN MICE 
Liver regeneration following toxic injury to liver is known to follow dose-response 
principles. Liver regeneration increases with dose of toxicant proportionate to injury until 
a threshold dose, beyond which the ability of liver to regenerate is impaired (Mehendale 
2005). Based on this principle, we developed a novel incremental dose model to study 
mechanisms of liver regeneration after APAP-induced hepatotoxicity utilizing two doses 
of APAP in mice.  A lower dose (300 mg/kg) that caused extensive liver injury but also 
significant compensatory regeneration leading to regression of injury and spontaneous 
recovery; and a higher dose (600 mg/kg) that inhibited liver regeneration resulting in 
sustained injury and decreased survival. We performed a comprehensive analysis of 
several signaling pathways known to be involved in liver regeneration and identified 
pathways which are potentially important for liver regeneration after APAP-induced 
hepatotoxicity. The approach of using two doses not only identified proliferative 
signaling pathways that correlated with robust liver regeneration after moderate APAP 
overdose, but more importantly provided us insight about potential mechanisms for 
impaired liver regeneration after the higher dose of APAP. Understanding the 
mechanism of impaired liver regeneration after high doses of APAP is more relevant 
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clinically, as high doses simulate pathophysiology of patients which cannot recover 
spontaneously after APAP overdose and require liver transplantation.  
Very interestingly, growth factor signaling via EGFR and c-Met and downstream MAPKs 
(ERK, p38 and JNK), were dose-dependently activated and remain highly activated 
even after the higher dose of APAP, where regeneration was inhibited. Growth factors 
such as EGFR ligands and HGF (ligand of c-Met) are known to play a critical role in 
hepatocyte proliferation and liver regeneration after PH (Michalopoulos 2007). In fact, 
EGFR ligands and HGF are the only known direct mitogens, which can cause 
hepatocyte proliferation in serum free medium. Our results question administration of 
growth factors as a therapeutic strategy after APAP-induced ALF. This observation is 
consistent with previous reports that administration of growth factors did not affect liver 
regeneration in dogs after APAP-induced ALF (Francavilla, Azzarone et al. 1993). Also 
patients who died after APAP-induced ALF were found to have higher amount of HGF 
circulating in the plasma (Hughes, Zhang et al. 1994). Similarly, IL-6/STAT-3 signaling 
has been reported to be important for liver regeneration after APAP-induced 
hepatotoxicity using IL6 KO mice (James, Lamps et al. 2003). However, in our 
incremental dose model, IL6/STAT-3 signaling remained highly activated even after the 
higher dose of APAP, where regeneration was inhibited.   
Our study revealed that marked inhibition of regeneration at the higher dose is 
not due to lack of viable hepatocytes as more than 50% hepatocytes were viable at this 
dose even at the peak injury.  In fact, peak injury was not remarkably different at two 
doses, while liver regeneration was remarkably impaired only at the higher dose. 
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Impaired liver regeneration at the higher dose even in presence of pro-proliferative 
signaling indicated possibility that some anti-proliferative signaling is blocking liver 
regeneration at higher dose counteracting the pro-regenerative signaling. Activation of 
cell cycle inhibitors such as p21 and cell cycle arrest at the higher dose supported this 
possibility. Moreover, some of the known regenerative pathways, which are highly 
activated in APAP600, may be actively involved in inhibiting regeneration. For instance, 
over-activation of p38  (Koteish, Yang et al. 2002, Horimoto, Fulop et al. 2004) and 
IL6/STAT3 signaling (Wustefeld, Rakemann et al. 2000, Torbenson, Yang et al. 2002) 
has been associated with decreased regeneration in the PH model. Further, sustained 
activation of these mediators was correlated with induction of p21 and inhibition of 
Cyclin D1, which is consistent with our data. Comprehensive studies focused on 
investigating role of cell cycle inhibitors in impaired liver regeneration after severe APAP 
overdose will be conducted in future. These studies will elucidate mechanisms of cell 
cycle arrest and facilitate discovering strategies to overcome the barriers of liver 
regeneration.  
Apart from activation of anti-proliferative signaling at the higher dose, some specific 
proliferative signaling pathways were inhibited at the higher dose. These pathways were 
specifically activated after the lower dose of APAP correlating with robust regenerative 
response. These included canonical Wnt/β-catenin and TNF-α/NF-κB signaling 
pathways. This was further supported by our ChIP analysis, which demonstrated that 
the binding of transcription factors β-catenin and NF-κB to Cyclin D1 was diminished at 
higher dose of APAP, correlating with decreased induction of Cyclin D1. Our study 
suggested that stimulating these pro-regenerative pathways may be a potential strategy 
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for development of novel regenerative therapies of APAP overdose, which warrant 
further investigation. Role of β-catenin signaling was comprehensively studied in later 
part of this dissertation work. Role of TNF receptor in liver regeneration after APAP 
overdose (Chiu, Gardner et al. 2003, James, Kurten et al. 2005) and positive correlation 
of NF-κB DNA binding with liver regeneration after APAP overdose has been reported 
previously (Yang, Miki et al. 2009, Yang, Zhang et al. 2011, Yang, Zhang et al. 2012). 
One the future direction of this work will be to investigate if stimulation of TNF-α/NF-κB 
pathway after the higher dose of APAP can improve liver regeneration, recovery and 
outcome.   
Overall, our work established a novel model to study liver regeneration after APAP-
induced toxicity in mice. This is first systematic study, to our knowledge, which 
comprehensively investigated the mechanisms of liver regeneration after APAP-induced 
hepatotoxicity. Further, our work with incremental doses of APAP revealed dose-
dependent differential regulation of pro-regenerative pathways after APAP 
hepatotoxicity which greatly improved our understanding of the mechanism of liver 
regeneration compared to single dose models. Our worked identified several potential 
regulators of liver regeneration after APAP-overdose which will be investigated 
comprehensively in future for potential development of regenerative therapies. In future, 
more doses of APAP can be included in this model of regeneration (to make it more 
robust) in order to gain more insights on differential dose-dependent alteration of liver 
regeneration and underlying mechanisms. Finally, our studies also indicate that 
concomitant inhibition of anti-proliferative pathways and activation of pro-regenerative 
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pathways may have a promising future in developing regenerative therapies for APAP-
induced ALF patients. 
5.2 ROLE OF β-CATENIN SIGNALING IN LIVER REGENERATION AFTER APAP 
OVERDOSE 
β-catenin has been emerged to be an important player in liver regeneration after PH 
(Nejak-Bowen and Monga 2011). Various studies in rodent model have demonstrated 
that liver specific deletion of β-catenin diminishes liver regeneration (Tan, Behari et al. 
2006, Sekine, Gutierrez et al. 2007), while overexpression of β-catenin accelerates liver 
regeneration after PH (Nejak-Bowen, Thompson et al. 2010). Further, our previous work 
showed that liver regeneration after APAP overdose is impaired in hepatocyte specific 
β-catenin KO mice (Apte, Singh et al. 2009). Our incremental dose model of APAP 
demonstrated that β-catenin signaling is inhibited after severe APAP overdose in mice, 
where liver regeneration is delayed and inhibited. Therefore, we investigated whether 
stimulation of β-catenin signaling can improve liver regeneration parameters after 
severe APAP-induced hepatotoxicity. We utilized a transgenic mouse model that 
overexpresses a stable form of β-catenin in the liver. Our work demonstrated that 
overexpression of β-catenin can improve liver regeneration parameters even after 
severe APAP hepatotoxicity secondary to timely induction of Cyclin D1. Importantly, 
liver injury parameters were not altered by overexpression of β-catenin suggesting 
regeneration can be modulated independent of injury. Our data show that stimulating β-
catenin could be a viable approach for improving liver regeneration in APAP-induced 
ALF patients. One of the future directions of this work is to screen repurposing libraries 
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to find novel stimulators of β-catenin signaling and to investigate their potential to 
improve liver regeneration after APAP hepatotoxicity for development of novel 
regenerative therapy.  
5.3 ROLE OF GSK3 SIGNALING IN LIVER REGENERATION AFTER APAP 
OVERDOSE 
Although our work using transgenic mice demonstrated a role of β-catenin signaling in 
liver regeneration after APAP-induced hepatotoxicity, we wanted to investigate if we can 
modulate liver regeneration after APAP overdose by pharmacological interventions. 
Such translational investigations would be more significant from clinical perspective. 
GSK3 inhibitors are known to activate β-catenin signaling and are currently under 
preclinical and clinical investigation for various other pathological conditions (Doble and 
Woodgett 2003, Kaidanovich-Beilin and Woodgett 2011). However, apart from β-
catenin, GKS3 can regulate a myriad of other cell proliferation mediators in both positive 
and negative manner (Jope and Johnson 2004, Kaidanovich-Beilin and Woodgett 2011, 
Sutherland 2011). Previous studies using PH model have demonstrated deleterious 
effect of GSK3 inhibition/ downregulation on liver regeneration (Chen, Yang et al. 2007, 
Jin, Wang et al. 2009, Sekiya and Suzuki 2011). In contrast, GSK3 inhibition also 
reported to mediate in vitro expansion of hepatocytes (Ito, Kamiya et al. 2012). Our 
incremental dose model demonstrated that GSK3β is rapidly inactivated preceding 
robust liver regeneration response after moderate APAP overdose. Inactivation of 
GSK3β was greatly diminished at the higher dose of APAP, where liver regeneration 
was remarkably attenuated and delayed. Thus, GSK3β inactivation positively correlated 
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with β-catenin activation and robust liver regeneration. Therefore, we investigated if 
inactivation of GSK3β by pharmacological intervention would improve liver regeneration 
after severe APAP overdose. We demonstrated that treatment with L803-mts, a 
substrate-competitive GSK3 inhibitor, as late as 4 hr after APAP, can lead to early 
initiation of liver regeneration after severe APAP overdose. Early cell cycle initiation in 
hepatocytes after GSK3 inhibition was associated with increased activation of β-catenin 
signaling. Interestingly, early liver regeneration after GSK3 inhibition was also 
associated with improved survival. Time window of therapeutic effectiveness of GSK3 
inhibitor is expected to be much more in human considering the pathogenesis of APAP 
hepatotoxicity is generally delayed in humans compared to mice (Xie, McGill et al. 
2014). Thus, our study highlights inhibition of GSK3 as a potential therapeutic strategy 
to improve liver regeneration after APAP-induced ALF. In future, other clinically 
promising GSK3 inhibitors will be investigated for potential pro-regenerative effects. 
From mechanistic standpoint, GSK3 KO strategy will be utilized in mice to further 
substantiate role of GSK3 in liver regeneration after APAP overdose. Further, role of 
other cell proliferation proteins regulated by GSK3, apart from β-catenin, will be 
investigated in liver regeneration after APAP overdose. 
5.4 ROLE OF EGFR SIGNALING IN LIVER REGENERATION AFTER APAP 
OVERDOSE 
Our incremental dose model revealed that EGFR signaling was remarkably activated 
after moderate APAP overdose, where injury was followed by robust liver regeneration. 
However, EGFR signaling was activated even more after higher dose of APAP, where 
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regeneration was inhibited. Although, this suggested that activated EGFR signaling is 
not sufficient to promote liver regeneration after severe APAP overdose, activated 
EGFR signaling may still be playing important role in compensatory liver regeneration 
after moderate APAP overdose that result in spontaneous recovery. In order to 
elucidate that, we investigated effect of EGFR inhibition (using specific pan-EGFR 
inhibitor, Canertinib) on liver regeneration after APAP overdose. To our surprise, early 
EGFR inhibition (1 hr post-APAP) strikingly attenuated APAP hepatotoxicity suggesting 
role of EGFR in development of APAP hepatotoxicity. Since liver regeneration is a 
compensatory response to liver injury after APAP toxicity, any alteration in liver injury 
can indirectly affect regeneration. Thus, direct role of EGFR inhibition on liver 
regeneration could not be tested. In order to investigate a direct role of EGFR activation 
on liver regeneration after APAP overdose, a delayed EGFR inhibition strategy (12 hr 
post-APAP) was utilized, such that APAP hepatotoxicity was already established. We 
demonstrated that delayed inhibition of EGFR almost completely abolished 
compensatory hepatocyte proliferation and decreased survival after moderate APAP 
overdose, which normally results in robust liver regeneration and spontaneous recovery.  
Failure of cell cycle progression was due to complete inhibition of cyclin D1 induction. 
Thus, our study established a critical role of EGFR signaling in liver regeneration after 
moderate APAP overdose. A number of previous studies in the PH model of liver 
regeneration show that inhibition or elimination of a single pathways can only delay or 
diminish liver regeneration but cannot permanently abolish liver regeneration 
(Michalopoulos 2007). Along similar lines, genetic ablation of EGFR or siRNA-mediated 
downregulation resulted in delayed liver regeneration after PH, which was eventually 
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compensated by upregulation of other pathways (Natarajan, Wagner et al. 2007, 
Paranjpe, Bowen et al. 2010). In contrast, in our study, delayed inhibition of EGFR after 
APAP overdose resulted in almost complete inhibition of liver regeneration, resulting in 
decreased survival. Thus, our data further highlight that the dynamics and mechanisms 
of liver regeneration are very different in APAP-induced ALF model (compared to PH), 
which advances very rapidly such that a timely regenerative response is imminently 
critical for final recovery.   
5.5 CONCLUDING REMARKS  
Several recent studies have demonstrated a critical role of timely liver regeneration in 
determining the final outcome after APAP overdose (Hu and Colletti 2008, Apte, Singh 
et al. 2009, Donahower, McCullough et al. 2010). Thus, stimulating liver regeneration in 
patients of APAP-induced ALF holds a great therapeutic potential. However, 
development of novel regenerative therapies for ALF is hampered because the 
mechanisms of liver regeneration after APAP-induced ALF have not extensively 
explored yet. Based on the dose-response principles, our work established a novel 
incremental dose model to identify potential regulators of liver regeneration after APAP 
overdose in mice. Our incremental dose model of APAP overdose showed that robust 
liver regeneration after moderate APAP overdose was associated with complete 
spontaneous recovery, while inhibited and delayed liver regeneration after severe APAP 
overdose was associated with impaired recovery and decreased survival. Further, 
several pro-regenerative signaling pathways (including β-catenin signaling) were 
differentially activated after moderate APAP overdose correlating with spontaneous 
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recovery and inhibited after severe APAP overdose correlating with impaired liver 
regeneration. Stimulating these pathways could prove to be a viable approach for 
improving liver regeneration and recovery after severe APAP hepatotoxicity, where 
spontaneous recovery is impaired.  Indeed, our work demonstrated that stimulation of β-
catenin signaling in mice can improve liver regeneration after severe APAP overdose. 
Moreover, our work established that inhibition of GSK3 (which is a negative regulator of 
β-catenin signaling) can lead to early liver regeneration and improvement in survival 
after APAP overdose in mice.  
Surprisingly, our incremental dose model revealed that several other known 
regenerative pathways (including growth factors signaling pathways such as EGFR 
signaling) were dose-dependently activated and remain highly activated even after 
severe APAP overdose, where liver regeneration is impaired. This suggests that 
activation of these pathways is not sufficient to promote liver regeneration after severe 
APAP overdose. These signaling pathways may still be playing important role in 
compensatory liver regeneration after moderate APAP overdose, which normally results 
in spontaneous recovery. Indeed, our work demonstrated that inhibition of EGFR after 
moderate APAP overdose can lead to impairment of liver regeneration and decreased 
survival.  
Overall, our incremental dose model will be critical in improving mechanistic 
understanding of the differences between spontaneous transplant free survival vs 
transplant-assisted survival and ALF-related deaths observed in APAP overdose 
patients. Further, our work demonstrates that stimulating liver regeneration could be a 
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viable therapeutic strategy and justifies further investigation of novel therapeutic 
strategies to stimulate liver regeneration after APAP-induced hepatotoxicity, which are 
currently extremely underexplored. Regenerative therapies at least could be helpful in 
bridging the time-gap before liver is available for transplantation to ALF patients. To 
conclude, this is the first systematic study to our knowledge, which comprehensively 
investigated the mechanisms of liver regeneration after APAP-induced ALF and will 
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